[Congressional Record Volume 162, Number 76 (Friday, May 13, 2016)]
[House]
[Pages H2355-H2374]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




            COMPREHENSIVE ADDICTION AND RECOVERY ACT OF 2016

  Mrs. BROOKS of Indiana. Mr. Speaker, pursuant to House Resolution 
725, I call up the bill (S. 524) to authorize the Attorney General to 
award grants to address the national epidemics of prescription opioid 
abuse and heroin use, and ask for its immediate consideration in the 
House.
  The Clerk read the title of the bill.
  The SPEAKER pro tempore. Pursuant to House Resolution 725, an 
amendment in the nature of a substitute described in the first section 
of that resolution is adopted, and the bill, as amended, is considered 
read.
  The text of the bill, as amended, is as follows:

                                 S. 524

       Be it enacted by the Senate and House of Representatives of 
     the United States of America in Congress assembled,

     SECTION 1. TABLE OF CONTENTS.

       The table of contents for this Act is as follows:

Sec. 1. Table of Contents.

    TITLE I--PAIN MANAGEMENT BEST PRACTICES INTER-AGENCY TASK FORCE

Sec. 101. Development of best practices for the use of prescription 
              opioids.

           TITLE II--COMPREHENSIVE OPIOID ABUSE REDUCTION ACT

Sec. 201. Short title.
Sec. 202. Comprehensive Opioid Abuse Grant Program.
Sec. 203. Audit and accountability of grantees.
Sec. 204. Veterans treatment courts.
Sec. 205. Emergency Federal law enforcement assistance.
Sec. 206. Inclusion of services for pregnant women under family-based 
              substance abuse grants.
Sec. 207. GAO study and report on Department of Justice programs and 
              research relative to substance use and substance use 
              disorders among adolescents and young adults.

                TITLE III--JASON SIMCAKOSKI PROMISE ACT

Sec. 301. Short title.
Sec. 302. Improvement of opioid safety measures by Department of 
              Veterans Affairs.
Sec. 303. Strengthening of joint working group on pain management of 
              the Department of Veterans Affairs and the Department of 
              Defense.
Sec. 304. Review, investigation, and report on use of opioids in 
              treatment by Department of Veterans Affairs.
Sec. 305. Mandatory disclosure of certain veteran information to State 
              controlled substance monitoring programs.
Sec. 306. Modification to limitation on awards and bonuses.

             TITLE IV--KINGPIN DESIGNATION IMPROVEMENT ACT

Sec. 401. Short title.
Sec. 402. Protection of classified information in Federal court 
              challenges relating to designations under the Narcotics 
              Kingpin Designation Act.

                 TITLE V--GOOD SAMARITAN ASSESSMENT ACT

Sec. 501. Short title.
Sec. 502. Finding.
Sec. 503. GAO Study on Good Samaritan laws pertaining to treatment of 
              opioid overdoses.
Sec. 504. Definitions.

                           TITLE VI--OPEN ACT

Sec. 601. Short title.
Sec. 602. Evaluation of performance of Department of Justice program.
Sec. 603. Evaluation of performance of Department of Health and Human 
              Services program.
Sec. 604. Definition.
Sec. 605. No additional funds authorized.
Sec. 606. Matters regarding certain Federal law enforcement assistance.

          TITLE VII--INFANT PLAN OF SAFE CARE IMPROVEMENT ACT

Sec. 701. Short title.
Sec. 702. Best practices for development of plans of safe care.
Sec. 703. State plans.
Sec. 704. Data reports.
Sec. 705. Monitoring and oversight.
Sec. 706. Rule of construction.

                   TITLE VIII--NAS HEALTHY BABIES ACT

Sec. 801. Short title.
Sec. 802. GAO report on neonatal abstinence syndrome (NAS).
Sec. 803. Excluding abuse-deterrent formulations of prescription drugs 
              from the Medicaid additional rebate requirement for new 
              formulations of prescription drugs.
Sec. 804. Limiting disclosure of predictive modeling and other 
              analytics technologies to identify and prevent waste, 
              fraud, and abuse.
Sec. 805. Medicaid Improvement Fund.

            TITLE IX--CO-PRESCRIBING TO REDUCE OVERDOSES ACT

Sec. 901. Short title.
Sec. 902. Opioid overdose reversal drugs prescribing grant program.
Sec. 903. Providing information to prescribers in certain Federal 
              health care and medical facilities on best practices for 
              prescribing opioid overdose reversal drugs.
Sec. 904. Authorization of appropriations.
Sec. 905. Cut-Go Compliance.

   TITLE X--IMPROVING TREATMENT FOR PREGNANT AND POSTPARTUM WOMEN ACT

Sec. 1001. Short title.

[[Page H2356]]

Sec. 1002. Reauthorization of residential treatment programs for 
              pregnant and postpartum women.
Sec. 1003. Pilot program grants for State substance abuse agencies.
Sec. 1004. Cut-Go Compliance.

       TITLE XI--VETERAN EMERGENCY MEDICAL TECHNICIAN SUPPORT ACT

Sec. 1101. Short title.
Sec. 1102. Assisting veterans with military emergency medical training 
              to meet requirements for becoming civilian emergency 
              medical technicians.

                   TITLE XII--JOHN THOMAS DECKER ACT

Sec. 1201. Short title.
Sec. 1202. Information materials and resources to prevent addiction 
              related to youth sports injuries.

                         TITLE XIII--LALI'S LAW

Sec. 1301. Short title.
Sec. 1302. Opioid overdose reversal medication access and education 
              grant programs.
Sec. 1303. Cut-Go Compliance.

               TITLE XIV--REDUCING UNUSED MEDICATIONS ACT

Sec. 1401. Short title.
Sec. 1402. Partial fills of schedule II controlled substances.

               TITLE XV--OPIOID REVIEW MODERNIZATION ACT

Sec. 1501. Short title.
Sec. 1502. FDA opioid action plan.
Sec. 1503. Prescriber education.
Sec. 1504. Guidance on evaluating the abuse deterrence of generic solid 
              oral opioid drug products.

        TITLE XVI--EXAMINING OPIOID TREATMENT INFRASTRUCTURE ACT

Sec. 1601. Short title.
Sec. 1602. Study on treatment infrastructure.

 TITLE XVII--OPIOID USE DISORDER TREATMENT EXPANSION AND MODERNIZATION 
                                  ACT

Sec. 1701. Short title.
Sec. 1702. Finding.
Sec. 1703. Opioid use disorder treatment modernization.
Sec. 1704. Sense of Congress.
Sec. 1705. Partial fills of schedule II controlled substances.

 TITLE XVIII--NATIONAL ALL SCHEDULES PRESCRIPTION ELECTRONIC REPORTING 
                          REAUTHORIZATION ACT

Sec. 1801. Short title.
Sec. 1802. Amendment to purpose.
Sec. 1803. Amendments to controlled substance monitoring program.

    TITLE I--PAIN MANAGEMENT BEST PRACTICES INTER-AGENCY TASK FORCE

     SEC. 101. DEVELOPMENT OF BEST PRACTICES FOR THE USE OF 
                   PRESCRIPTION OPIOIDS.

       (a) Definitions.--In this section--
       (1) the term ``Secretary'' means the Secretary of Health 
     and Human Services; and
       (2) the term ``task force'' means the Pain Management Best 
     Practices Inter-Agency Task Force convened under subsection 
     (b).
       (b) Inter-Agency Task Force.--Not later than December 14, 
     2018, the Secretary, in cooperation with the Secretary of 
     Veterans Affairs, the Secretary of Defense, and the 
     Administrator of the Drug Enforcement Administration, shall 
     convene a Pain Management Best Practices Inter-Agency Task 
     Force to review, modify, and update, as appropriate, best 
     practices for pain management (including chronic and acute 
     pain) and prescribing pain medication.
       (c) Membership.--The task force shall be comprised of--
       (1) representatives of--
       (A) the Department of Health and Human Services;
       (B) the Department of Veterans Affairs;
       (C) the Food and Drug Administration;
       (D) the Department of Defense;
       (E) the Drug Enforcement Administration;
       (F) the Centers for Disease Control and Prevention;
       (G) the Health Resources and Services Administration;
       (H) the Indian Health Service;
       (I) the National Academy of Medicine;
       (J) the National Institutes of Health;
       (K) the Office of National Drug Control Policy;
       (L) the Substance Abuse and Mental Health Services 
     Administration; and
       (M) the Office of Women's Health;
       (2) State medical boards;
       (3) subject to subsection (e), physicians, dentists, and 
     nonphysician prescribers;
       (4) hospitals;
       (5) subject to subsection (e), pharmacists and pharmacies;
       (6) first responders;
       (7) experts in the fields of pain research and addiction 
     research;
       (8) experts in the fields of adolescent and young adult 
     addiction research;
       (9) representatives of--
       (A) pain management professional organizations;
       (B) the mental health treatment community;
       (C) the addiction treatment and recovery community;
       (D) pain advocacy groups;
       (E) veteran service organizations; and
       (F) groups with expertise on overdose reversal;
       (10) a person in recovery from addiction to medication for 
     chronic pain;
       (11) a person in recovery from addiction to medication for 
     chronic pain, whose addiction began in adolescence or young 
     adulthood;
       (12) a person with chronic pain;
       (13) an expert on active duty military, armed forces 
     personnel, and veteran health and prescription opioid 
     addiction;
       (14) an expert in the field of minority health; and
       (15) other stakeholders, as the Secretary determines 
     appropriate.
       (d) Condition on Participation on Task Force.--An 
     individual representing a profession or entity described in 
     paragraph (3) or (5) of subsection (c) may not serve as a 
     member of the task force unless such individual--
       (1) is currently licensed in a State in which such 
     individual is practicing (as defined by such State) such 
     profession (or, in the case of an individual representing an 
     entity, a State in which the entity is engaged in business); 
     and
       (2) is currently practicing (as defined by such State) such 
     profession (or, in the case of an individual representing an 
     entity, the entity is in operation).
       (e) Duties.--The task force shall--
       (1) not later than 180 days after the date on which the 
     task force is convened under subsection (b), review, modify, 
     and update, as appropriate, best practices for pain 
     management (including chronic and acute pain) and prescribing 
     pain medication, taking into consideration--
       (A) existing pain management research;
       (B) research on trends in areas and communities in which 
     the prescription opioid abuse rate and fatality rate exceed 
     the national average prescription opioid abuse rate and 
     fatality rate;
       (C) recommendations from relevant conferences and existing 
     relevant evidence-based guidelines;
       (D) ongoing efforts at the State and local levels and by 
     medical professional organizations to develop improved pain 
     management strategies, including consideration of differences 
     within and between classes of opioids, the availability of 
     opioids with abuse deterrent technology, and pharmacological, 
     nonpharmacological, medical device alternatives to opioids to 
     reduce opioid monotherapy in appropriate cases and the 
     coordination of information collected from State prescription 
     drug monitoring programs for the purpose of preventing the 
     diversion of pain medication;
       (E) ongoing efforts at the Federal, State, and local levels 
     to examine the potential benefits of electronic prescribing 
     of opioids, including any public comments collected in the 
     course of those efforts;
       (F) the management of high-risk populations, other than 
     populations who suffer pain, who--
       (i) may use or be prescribed benzodiazepines, alcohol, and 
     diverted opioids; or
       (ii) receive opioids in the course of medical care;
       (G) the distinct needs of adolescents and young adults with 
     respect to pain management, pain medication, substance use 
     disorder, and medication-assisted treatment;
       (H) the 2016 Guideline for Prescribing Opioids for Chronic 
     Pain issued by the Centers for Disease Control and 
     Prevention;
       (I) the practice of co-prescribing naloxone for both pain 
     patients receiving chronic opioid therapy and patients being 
     treated for opioid use disorders;
       (J) research that has been, or is being, conducted or 
     supported by the Federal Government on prevention of, 
     treatment for, and recovery from substance use by and 
     substance use disorders among adolescents and young adults 
     relative to any unique circumstances (including social and 
     biological circumstances) of adolescents and young adults 
     that may make adolescent-specific and young adult-specific 
     treatment protocols necessary, including any effects that 
     substance use and substance use disorders may have on brain 
     development and the implications for treatment and recovery;
       (K) Federal non-research programs and activities that 
     address prevention of, treatment for, and recovery from 
     substance use by and substance use disorders among 
     adolescents and young adults, including an assessment of the 
     effectiveness of such programs and activities in--
       (i) preventing substance use by and substance use disorders 
     among adolescents and young adults;
       (ii) treating such adolescents and young adults in a way 
     that accounts for any unique circumstances faced by 
     adolescents and young adults; and
       (iii) supporting long-term recovery among adolescents and 
     young adults; and
       (L) gaps that have been identified by Federal officials and 
     experts in Federal efforts relating to prevention of, 
     treatment for, and recovery from substance use by and 
     substance use disorders among adolescents and young adults, 
     including gaps in research, data collection, and measures to 
     evaluate the effectiveness of Federal efforts, and the 
     reasons for such gaps;
       (2) solicit and take into consideration public comment on 
     the practices developed under paragraph (1), amending such 
     best practices if appropriate;
       (3) develop a strategy for disseminating information about 
     the best practices developed under paragraphs (1) and (2) to 
     prescribers, pharmacists, State medical boards, educational 
     institutions that educate prescribers and pharmacists, and 
     other parties, as the Secretary determines appropriate;
       (4) review, modify, and update best practices for pain 
     management and prescribing pain medication, specifically as 
     it pertains to physician education and consumer education; 
     and
       (5) examine and identify--
       (A) the extent of the need for the development of new 
     pharmacological, nonpharmacological, and medical device 
     alternatives to opioids;
       (B) the current status of research efforts to develop such 
     alternatives; and
       (C) the pharmacological, nonpharmacological, and medical 
     device alternatives to opioids that

[[Page H2357]]

     are currently available that could be better utilized.
       (f) Consideration of Study Results.--In reviewing, 
     modifying, and updating, best practices for pain management 
     and prescribing pain medication, the task force shall take 
     into consideration existing private sector, State, and local 
     government efforts related to pain management and prescribing 
     pain medication.
       (g) Limitation.--The task force shall not have rulemaking 
     authority.
       (h) Report.--Not later than 270 days after the date on 
     which the task force is convened under subsection (b), the 
     task force shall submit to Congress a report that includes--
       (1) the strategy for disseminating best practices for pain 
     management (including chronic and acute pain) and prescribing 
     pain medication, as developed under subsection (e);
       (2) the results of a feasibility study on linking the best 
     practices described in paragraph (1) to receiving and 
     renewing registrations under section 303(f) of the Controlled 
     Substances Act (21 U.S.C. 823(f));
       (3) recommendations for effectively applying the best 
     practices described in paragraph (1) to improve prescribing 
     practices at medical facilities, including medical facilities 
     of the Veterans Health Administration and Indian Health 
     Service;
       (4) the modified and updated best practices described in 
     subsection (e)(4); and
       (5) the results of the examination and identification 
     conducted pursuant to subsection (e)(4), and recommendations 
     regarding--
       (A) the development of new pharmacological, 
     nonpharmacological, and medical device alternatives to 
     opioids; and
       (B) the improved utilization of pharmacological, 
     nonpharmacological, and medical device alternatives to 
     opioids that are currently available.

           TITLE II--COMPREHENSIVE OPIOID ABUSE REDUCTION ACT

     SEC. 201. SHORT TITLE.

       This title may be cited as the ``Comprehensive Opioid Abuse 
     Reduction Act of 2016''.

     SEC. 202. COMPREHENSIVE OPIOID ABUSE GRANT PROGRAM.

       (a) In General.--Title I of the Omnibus Crime Control and 
     Safe Streets Act of 1968 (42 U.S.C. 3711 et seq.) is amended 
     by adding at the end the following:

          ``PART LL--COMPREHENSIVE OPIOID ABUSE GRANT PROGRAM

     ``SEC. 3021. DESCRIPTION.

       ``(a) Grants Authorized.--From amounts made available to 
     carry out this part, the Attorney General may make grants to 
     States, units of local government, and Indian tribes, for use 
     by the State, unit of local government, or Indian tribe to 
     provide services primarily relating to opioid abuse, 
     including for any one or more of the following:
       ``(1) Developing, implementing, or expanding a treatment 
     alternative to incarceration program, which may include--
       ``(A) pre-booking or post-booking components, which may 
     include the activities described in part DD or HH of this 
     title;
       ``(B) training for criminal justice agency personnel on 
     substance use disorders and co-occurring mental illness and 
     substance use disorders;
       ``(C) a mental health court, including the activities 
     described in part V of this title;
       ``(D) a drug court, including the activities described in 
     part EE of this title;
       ``(E) a veterans treatment court program, including the 
     activities described in subsection (i) of section 2991 of 
     this title;
       ``(F) a focus on parents whose incarceration could result 
     in their children entering the child welfare system; and
       ``(G) a community-based substance use diversion program 
     sponsored by a law enforcement agency.
       ``(2) In the case of a State, facilitating or enhancing 
     planning and collaboration between State criminal justice 
     agencies and State substance abuse systems in order to more 
     efficiently and effectively carry out programs described in 
     paragraph (1) that address problems related to opioid abuse.
       ``(3) Providing training and resources for first responders 
     on carrying and administering an opioid overdose reversal 
     drug or device approved by the Food and Drug Administration, 
     and purchasing such a drug or device for first responders who 
     have received such training to carry and administer.
       ``(4) Investigative purposes to locate or investigate 
     illicit activities related to the unlawful distribution of 
     opioids.
       ``(5) Developing, implementing, or expanding a medication-
     assisted treatment program used or operated by a criminal 
     justice agency, which may include training criminal justice 
     agency personnel on medication-assisted treatment, and 
     carrying out the activities described in part S of this 
     title.
       ``(6) In the case of a State, developing, implementing, or 
     expanding a prescription drug monitoring program to collect 
     and analyze data related to the prescribing of schedules II, 
     III, and IV controlled substances through a centralized 
     database administered by an authorized State agency, which 
     includes tracking the dispensation of such substances, and 
     providing for interoperability and data sharing with other 
     States.
       ``(7) Developing, implementing, or expanding a program to 
     prevent and address opioid abuse by juveniles.
       ``(8) Developing, implementing, or expanding an integrated 
     and comprehensive opioid abuse response program, including 
     prevention and recovery programs.
       ``(9) Developing, implementing, or expanding a program 
     (which may include demonstration projects) to utilize 
     technology that provides a secure container for prescription 
     drugs that would prevent individuals, particularly 
     adolescents, from gaining access to opioid medications that 
     are lawfully prescribed for other individuals.
       ``(10) Developing, implementing, or expanding a program to 
     prevent and address opioid abuse by veterans.
       ``(11) Developing, implementing, or expanding a 
     prescription drug take-back program.
       ``(b) Contracts and Subawards.--A State, unit of local 
     government, or Indian tribe may, in using a grant under this 
     subpart for purposes authorized by subsection (a), use all or 
     a portion of that grant to contract with or make one or more 
     subawards to one or more--
       ``(1) local or regional organizations that are private and 
     nonprofit, including faith-based organizations;
       ``(2) units of local government; or
       ``(3) tribal organizations.
       ``(c) Program Assessment Component; Waiver.--
       ``(1) Program assessment component.--Each program funded 
     under this subpart shall contain a program assessment 
     component, developed pursuant to guidelines established by 
     the Attorney General, in coordination with the National 
     Institute of Justice.
       ``(2) Waiver.--The Attorney General may waive the 
     requirement of paragraph (1) with respect to a program if, in 
     the opinion of the Attorney General, the program is not of 
     sufficient size to justify a full program assessment.
       ``(d) Administrative Costs.--Not more than 10 percent of a 
     grant made under this subpart may be used for costs incurred 
     to administer such grant.
       ``(e) Period.--The period of a grant made under this part 
     may not be longer than 4 years, except that renewals and 
     extensions beyond that period may be granted at the 
     discretion of the Attorney General.

     ``SEC. 3022. APPLICATIONS.

       ``To request a grant under this part, the chief executive 
     officer of a State, unit of local government, or Indian tribe 
     shall submit an application to the Attorney General at such 
     time and in such form as the Attorney General may require. 
     Such application shall include the following:
       ``(1) A certification that Federal funds made available 
     under this subpart will not be used to supplant State, local, 
     or tribal funds, but will be used to increase the amounts of 
     such funds that would, in the absence of Federal funds, be 
     made available for the activities described in section 
     3021(a).
       ``(2) An assurance that, for each fiscal year covered by an 
     application, the applicant shall maintain and report such 
     data, records, and information (programmatic and financial) 
     as the Attorney General may reasonably require.
       ``(3) A certification, made in a form acceptable to the 
     Attorney General and executed by the chief executive officer 
     of the applicant (or by another officer of the applicant, if 
     qualified under regulations promulgated by the Attorney 
     General), that--
       ``(A) the programs to be funded by the grant meet all the 
     requirements of this part;
       ``(B) all the information contained in the application is 
     correct;
       ``(C) there has been appropriate coordination with affected 
     agencies; and
       ``(D) the applicant will comply with all provisions of this 
     part and all other applicable Federal laws.
       ``(4) An assurance that the applicant will work with the 
     Drug Enforcement Administration to develop an integrated and 
     comprehensive strategy to address opioid abuse.

     ``SEC. 3023. REVIEW OF APPLICATIONS.

       ``The Attorney General shall not finally disapprove any 
     application (or any amendment to that application) submitted 
     under this part without first affording the applicant 
     reasonable notice of any deficiencies in the application and 
     opportunity for correction and reconsideration.

     ``SEC. 3024. EQUITABLE DISTRIBUTION OF FUNDS.

       ``In awarding grants under this part, the Attorney General 
     shall ensure equitable distribution of funds based on the 
     following:
       ``(1) The geographic distribution of grants under this 
     part, taking into consideration the needs of underserved 
     populations, including rural and tribal communities.
       ``(2) The needs of communities to address the problems 
     related to opioid abuse, taking into consideration the 
     prevalence of opioid abuse and overdose-related death in a 
     community.

     ``SEC. 3025. DEFINITIONS.

       ``In this part:
       ``(1) The term `first responder' includes a firefighter, 
     law enforcement officer, paramedic, emergency medical 
     technician, or other individual (including an employee of a 
     legally organized and recognized volunteer organization, 
     whether compensated or not), who, in the course of 
     professional duties, responds to fire, medical, hazardous 
     material, or other similar emergencies.
       ``(2) The term `medication-assisted treatment' means the 
     use of medications approved by the Food and Drug 
     Administration for the treatment of opioid abuse.
       ``(3) The term `opioid' means any drug, including heroin, 
     having an addiction-forming or addiction-sustaining liability 
     similar to morphine or being capable of conversion into a 
     drug having such addiction-forming or addiction-sustaining 
     liability.
       ``(4) The term `schedule II, III, or IV controlled 
     substance' means a controlled substance that is listed on 
     schedule II, schedule III, or schedule IV of section 202(c) 
     of the Controlled Substances Act (21 U.S.C. 812(c)).
       ``(5) The terms `drug' and `device' have the meanings given 
     those terms in section 201 of the Federal Food, Drug, and 
     Cosmetic Act (21 U.S.C. 321).
       ``(6) The term `criminal justice agency' means a State, 
     local, or tribal--
       ``(A) court;

[[Page H2358]]

       ``(B) prison;
       ``(C) jail;
       ``(D) law enforcement agency; or
       ``(E) other agency that performs the administration of 
     criminal justice, including prosecution, pretrial services, 
     and community supervision.
       ``(7) The term `tribal organization' has the meaning given 
     that term in section 4 of the Indian Self-Determination and 
     Education Assistance Act (25 U.S.C. 450b).''.
       (b) Authorization of Appropriations.--Section 1001(a) of 
     the Omnibus Crime Control and Safe Streets Act of 1968 (42 
     U.S.C. 3793(a)) is amended by inserting after paragraph (26) 
     the following:
       ``(27) There are authorized to be appropriated to carry out 
     part LL $103,000,000 for each of fiscal years 2017 through 
     2021.''.

     SEC. 203. AUDIT AND ACCOUNTABILITY OF GRANTEES.

       (a) Definitions.--In this section--
       (1) the term ``covered grant program'' means a grant 
     program operated by the Department of Justice;
       (2) the term ``covered grantee'' means a recipient of a 
     grant from a covered grant program;
       (3) the term ``nonprofit'', when used with respect to an 
     organization, means an organization that is described in 
     section 501(c)(3) of the Internal Revenue Code of 1986, and 
     is exempt from taxation under section 501(a) of such Code; 
     and
       (4) the term ``unresolved audit finding'' means an audit 
     report finding in a final audit report of the Inspector 
     General of the Department of Justice that a covered grantee 
     has used grant funds awarded to that grantee under a covered 
     grant program for an unauthorized expenditure or otherwise 
     unallowable cost that is not closed or resolved during a 12-
     month period prior to the date on which the final audit 
     report is issued.
       (b) Audit Requirement.--Beginning in fiscal year 2016, and 
     annually thereafter, the Inspector General of the Department 
     of Justice shall conduct audits of covered grantees to 
     prevent waste, fraud, and abuse of funds awarded under 
     covered grant programs. The Inspector General shall determine 
     the appropriate number of covered grantees to be audited each 
     year.
       (c) Mandatory Exclusion.--A grantee that is found to have 
     an unresolved audit finding under an audit conducted under 
     subsection (b) may not receive grant funds under a covered 
     grant program in the fiscal year following the fiscal year to 
     which the finding relates.
       (d) Reimbursement.--If a covered grantee is awarded funds 
     under the covered grant program from which it received a 
     grant award during the 1-fiscal-year period during which the 
     covered grantee is ineligible for an allocation of grant 
     funds under subsection (c), the Attorney General shall--
       (1) deposit into the General Fund of the Treasury an amount 
     that is equal to the amount of the grant funds that were 
     improperly awarded to the covered grantee; and
       (2) seek to recoup the costs of the repayment to the Fund 
     from the covered grantee that was improperly awarded the 
     grant funds.
       (e) Priority of Grant Awards.--The Attorney General, in 
     awarding grants under a covered grant program shall give 
     priority to eligible entities that during the 2-year period 
     preceding the application for a grant have not been found to 
     have an unresolved audit finding.
       (f) Nonprofit Requirements.--
       (1) Prohibition.--A nonprofit organization that holds money 
     in offshore accounts for the purpose of avoiding the tax 
     described in section 511(a) of the Internal Revenue Code of 
     1986, shall not be eligible to receive, directly or 
     indirectly, any funds from a covered grant program.
       (2) Disclosure.--Each nonprofit organization that is a 
     covered grantee shall disclose in its application for such a 
     grant, as a condition of receipt of such a grant, the 
     compensation of its officers, directors, and trustees. Such 
     disclosure shall include a description of the criteria relied 
     on to determine such compensation.

     SEC. 204. VETERANS TREATMENT COURTS.

       Section 2991 of the Omnibus Crime Control and Safe Streets 
     Act of 1968 (42 U.S.C. 3797aa) is amended--
       (1) by redesignating subsection (i) as subsection (j); and
       (2) by inserting after subsection (h) the following:
       ``(i) Assisting Veterans.--
       ``(1) Definitions.--In this subsection:
       ``(A) Peer to peer services or programs.--The term `peer to 
     peer services or programs' means services or programs that 
     connect qualified veterans with other veterans for the 
     purpose of providing support and mentorship to assist 
     qualified veterans in obtaining treatment, recovery, 
     stabilization, or rehabilitation.
       ``(B) Qualified veteran.--The term `qualified veteran' 
     means a preliminarily qualified offender who--
       ``(i) served on active duty in any branch of the Armed 
     Forces, including the National Guard or Reserves; and
       ``(ii) was discharged or released from such service under 
     conditions other than dishonorable.
       ``(C) Veterans treatment court program.--The term `veterans 
     treatment court program' means a court program involving 
     collaboration among criminal justice, veterans, and mental 
     health and substance abuse agencies that provides qualified 
     veterans with--
       ``(i) intensive judicial supervision and case management, 
     which may include random and frequent drug testing where 
     appropriate;
       ``(ii) a full continuum of treatment services, including 
     mental health services, substance abuse services, medical 
     services, and services to address trauma;
       ``(iii) alternatives to incarceration; or
       ``(iv) other appropriate services, including housing, 
     transportation, mentoring, employment, job training, 
     education, or assistance in applying for and obtaining 
     available benefits.
       ``(2) Veterans assistance program.--
       ``(A) In general.--The Attorney General, in consultation 
     with the Secretary of Veterans Affairs, may award grants 
     under this subsection to applicants to establish or expand--
       ``(i) veterans treatment court programs;
       ``(ii) peer to peer services or programs for qualified 
     veterans;
       ``(iii) practices that identify and provide treatment, 
     rehabilitation, legal, transitional, and other appropriate 
     services to qualified veterans who have been incarcerated; or
       ``(iv) training programs to teach criminal justice, law 
     enforcement, corrections, mental health, and substance abuse 
     personnel how to identify and appropriately respond to 
     incidents involving qualified veterans.
       ``(B) Priority.--In awarding grants under this subsection, 
     the Attorney General shall give priority to applications 
     that--
       ``(i) demonstrate collaboration between and joint 
     investments by criminal justice, mental health, substance 
     abuse, and veterans service agencies;
       ``(ii) promote effective strategies to identify and reduce 
     the risk of harm to qualified veterans and public safety; and
       ``(iii) propose interventions with empirical support to 
     improve outcomes for qualified veterans.''.

     SEC. 205. EMERGENCY FEDERAL LAW ENFORCEMENT ASSISTANCE.

       Section 609Y(a) of the Justice Assistance Act of 1984 (42 
     U.S.C. 10513(a)) is amended by striking ``September 30, 
     1984'' and inserting ``September 30, 2021''.

     SEC. 206. INCLUSION OF SERVICES FOR PREGNANT WOMEN UNDER 
                   FAMILY-BASED SUBSTANCE ABUSE GRANTS.

       Part DD of title I of the Omnibus Crime Control and Safe 
     Streets Act (42 U.S.C. 3797s et seq.) is amended--
       (1) in section 2921(2), by inserting before the period at 
     the end ``or pregnant women''; and
       (2) in section 2927--
       (A) in paragraph (1)(A), by inserting ``pregnant or'' 
     before ``a parent''; and
       (B) in paragraph (3), by inserting ``or pregnant women'' 
     after ``incarcerated parents''.

     SEC. 207. GAO STUDY AND REPORT ON DEPARTMENT OF JUSTICE 
                   PROGRAMS AND RESEARCH RELATIVE TO SUBSTANCE USE 
                   AND SUBSTANCE USE DISORDERS AMONG ADOLESCENTS 
                   AND YOUNG ADULTS.

       (a) Study.--The Comptroller General of the United States 
     shall conduct a study on how the Department of Justice, 
     through grant programs, is addressing prevention of, 
     treatment for, and recovery from substance use by and 
     substance use disorders among adolescents and young adults. 
     Such study shall include an analysis of each of the 
     following:
       (1) The research that has been, and is being, conducted or 
     supported pursuant to grant programs operated by the 
     Department of Justice on prevention of, treatment for, and 
     recovery from substance use by and substance use disorders 
     among adolescents and young adults, including an assessment 
     of--
       (A) such research relative to any unique circumstances 
     (including social and biological circumstances) of 
     adolescents and young adults that may make adolescent-
     specific and young adult-specific treatment protocols 
     necessary, including any effects that substance use and 
     substance use disorders may have on brain development and the 
     implications for treatment and recovery; and
       (B) areas of such research in which greater investment or 
     focus is necessary relative to other areas of such research.
       (2) Department of Justice non-research programs and 
     activities that address prevention of, treatment for, and 
     recovery from substance use by and substance use disorders 
     among adolescents and young adults, including an assessment 
     of the effectiveness of such programs and activities in 
     preventing substance use by and substance use disorders among 
     adolescents and young adults, treating such adolescents and 
     young adults in a way that accounts for any unique 
     circumstances faced by adolescents and young adults, and 
     supports long term recovery among adolescents and young 
     adults.
       (3) Gaps that have been identified by officials of the 
     Department of Justice or experts in the efforts supported by 
     grant programs operated by the Department of Justice relating 
     to prevention of, treatment for, and recovery from substance 
     use by and substance use disorders among adolescents and 
     young adults, including gaps in research, data collection, 
     and measures to evaluate the effectiveness of such efforts, 
     and the reasons for such gaps.
       (b) Report.--Not later than 2 years after the date of 
     enactment of this Act, the Comptroller General shall submit 
     to the appropriate committees of the Congress a report 
     containing the results of the study conducted under 
     subsection (a), including--
       (1) a summary of the findings of the study; and
       (2) recommendations based on the results of the study, 
     including recommendations for such areas of research and 
     legislative and administrative action as the Comptroller 
     General determines appropriate.

                TITLE III--JASON SIMCAKOSKI PROMISE ACT

     SEC. 301. SHORT TITLE.

       This title may be cited as the ``Promoting Responsible 
     Opioid Management and Incorporating Scientific Expertise 
     Act'' or the ``Jason Simcakoski PROMISE Act''.

     SEC. 302. IMPROVEMENT OF OPIOID SAFETY MEASURES BY DEPARTMENT 
                   OF VETERANS AFFAIRS.

       (a) Expansion of Opioid Safety Initiative.--
       (1) Inclusion of all medical facilities.--Not later than 
     180 days after the date of the enactment of this Act, the 
     Secretary of Veterans

[[Page H2359]]

     Affairs shall expand the Opioid Safety Initiative of the 
     Department of Veterans Affairs to include all medical 
     facilities of the Department.
       (2) Guidance.--The Secretary shall establish guidance that 
     each health care provider of the Department of Veterans 
     Affairs, before initiating opioid therapy to treat a patient 
     as part of the comprehensive assessment conducted by the 
     health care provider, use the Opioid Therapy Risk Report tool 
     of the Department of Veterans Affairs (or any subsequent 
     tool), which shall include information from the prescription 
     drug monitoring program of each participating State as 
     applicable, that includes the most recent information to date 
     relating to the patient that accessed such program to assess 
     the risk for adverse outcomes of opioid therapy for the 
     patient, including the concurrent use of controlled 
     substances such as benzodiazepines, as part of the 
     comprehensive assessment conducted by the health care 
     provider.
       (3) Enhanced standards.--The Secretary shall establish 
     enhanced standards with respect to the use of routine and 
     random urine drug tests for all patients before and during 
     opioid therapy to help prevent substance abuse, dependence, 
     and diversion, including--
       (A) that such tests occur not less frequently than once 
     each year; and
       (B) that health care providers appropriately order, 
     interpret and respond to the results from such tests to 
     tailor pain therapy, safeguards, and risk management 
     strategies to each patient.
       (b) Pain Management Education and Training.--
       (1) In general.--In carrying out the Opioid Safety 
     Initiative of the Department, the Secretary shall require all 
     employees of the Department responsible for prescribing 
     opioids to receive education and training described in 
     paragraph (2).
       (2) Education and training.--Education and training 
     described in this paragraph is education and training on pain 
     management and safe opioid prescribing practices for purposes 
     of safely and effectively managing patients with chronic 
     pain, including education and training on the following:
       (A) The implementation of and full compliance with the VA/
     DOD Clinical Practice Guideline for Management of Opioid 
     Therapy for Chronic Pain, including any update to such 
     guideline.
       (B) The use of evidence-based pain management therapies, 
     including cognitive-behavioral therapy, non-opioid 
     alternatives, and non-drug methods and procedures to managing 
     pain and related health conditions including medical devices 
     approved or cleared by the Food and Drug Administration for 
     the treatment of patients with chronic pain and complementary 
     alternative medicines.
       (C) Screening and identification of patients with substance 
     use disorder, including drug-seeking behavior, before 
     prescribing opioids, assessment of risk potential for 
     patients developing an addiction, and referral of patients to 
     appropriate addiction treatment professionals if addiction is 
     identified or strongly suspected.
       (D) Communication with patients on the potential harm 
     associated with the use of opioids and other controlled 
     substances, including the need to safely store and dispose of 
     supplies relating to the use of opioids and other controlled 
     substances.
       (E) Such other education and training as the Secretary 
     considers appropriate to ensure that veterans receive safe 
     and high-quality pain management care from the Department.
       (3) Use of existing program.--In providing education and 
     training described in paragraph (2), the Secretary shall use 
     the Interdisciplinary Chronic Pain Management Training Team 
     Program of the Department (or success program).
       (c) Pain Management Teams.--
       (1) In general.--In carrying out the Opioid Safety 
     Initiative of the Department, the director of each medical 
     facility of the Department shall identify and designate a 
     pain management team of health care professionals, which may 
     include board certified pain medicine specialists, 
     responsible for coordinating and overseeing pain management 
     therapy at such facility for patients experiencing acute and 
     chronic pain that is non-cancer related.
       (2) Establishment of protocols.--
       (A) In general.--In consultation with the Directors of each 
     Veterans Integrated Service Network, the Secretary shall 
     establish standard protocols for the designation of pain 
     management teams at each medical facility within the 
     Department.
       (B) Consultation on prescription of opioids.--Each protocol 
     established under subparagraph (A) shall ensure that any 
     health care provider without expertise in prescribing 
     analgesics or who has not completed the education and 
     training under subsection (b), including a mental health care 
     provider, does not prescribe opioids to a patient unless that 
     health care provider--
       (i) consults with a health care provider with pain 
     management expertise or who is on the pain management team of 
     the medical facility; and
       (ii) refers the patient to the pain management team for any 
     subsequent prescriptions and related therapy.
       (3) Report.--
       (A) In general.--Not later than 1 year after the date of 
     enactment of this Act, the director of each medical facility 
     of the Department shall submit to the Under Secretary for 
     Health and the director of the Veterans Integrated Service 
     Network in which the medical facility is located a report 
     identifying the health care professionals that have been 
     designated as members of the pain management team at the 
     medical facility pursuant to paragraph (1).
       (B) Elements.--Each report submitted under subparagraph (A) 
     with respect to a medical facility of the Department shall 
     include--
       (i) a certification as to whether all members of the pain 
     management team at the medical facility have completed the 
     education and training required under subsection (b);
       (ii) a plan for the management and referral of patients to 
     such pain management team if health care providers without 
     expertise in prescribing analgesics prescribe opioid 
     medications to treat acute and chronic pain that is non-
     cancer related; and
       (iii) a certification as to whether the medical facility--

       (I) fully complies with the stepped-care model of pain 
     management and other pain management policies contained in 
     Directive 2009-053 of the Veterans Health Administration, or 
     successor directive; or
       (II) does not fully comply with such stepped-care model of 
     pain management and other pain management policies but is 
     carrying out a corrective plan of action to ensure such full 
     compliance.

       (d) Tracking and Monitoring of Opioid Use.--
       (1) Prescription drug monitoring programs of states.--In 
     carrying out the Opioid Safety Initiative and the Opioid 
     Therapy Risk Report tool of the Department, the Secretary 
     shall--
       (A) ensure access by health care providers of the 
     Department to information on controlled substances, including 
     opioids and benzodiazepines, prescribed to veterans who 
     receive care outside the Department through the prescription 
     drug monitoring program of each State with such a program, 
     including by seeking to enter into memoranda of understanding 
     with States to allow shared access of such information 
     between States and the Department;
       (B) include such information in the Opioid Therapy Risk 
     Report; and
       (C) require health care providers of the Department to 
     submit to the prescription drug monitoring program of each 
     State information on prescriptions of controlled substances 
     received by veterans in that State under the laws 
     administered by the Secretary.
       (2) Report on tracking of data on opioid use.--Not later 
     than 18 months after the date of the enactment of this Act, 
     the Secretary shall submit to the Committee on Veterans' 
     Affairs of the Senate and the Committee on Veterans' Affairs 
     of the House of Representatives a report on the feasibility 
     and advisability of improving the Opioid Therapy Risk Report 
     tool of the Department to allow for more advanced real-time 
     tracking of and access to data on--
       (A) the key clinical indicators with respect to the 
     totality of opioid use by veterans;
       (B) concurrent prescribing by health care providers of the 
     Department of opioids in different health care settings, 
     including data on concurrent prescribing of opioids to treat 
     mental health disorders other than opioid use disorder; and
       (C) mail-order prescriptions of opioid prescribed to 
     veterans under the laws administered by the Secretary.
       (e) Availability of Opioid Receptor Antagonists.--
       (1) Increased availability and use.--
       (A) In general.--The Secretary shall maximize the 
     availability of opioid receptor antagonists approved by the 
     Food and Drug Administration, including naloxone, to 
     veterans.
       (B) Availability, training, and distributing.--In carrying 
     out subparagraph (A), not later than 90 days after the date 
     of the enactment of this Act, the Secretary shall--
       (i) equip each pharmacy of the Department with opioid 
     receptor antagonists approved by the Food and Drug 
     Administration to be dispensed to outpatients as needed; and
       (ii) expand the Overdose Education and Naloxone 
     Distribution program of the Department to ensure that all 
     veterans in receipt of health care under laws administered by 
     the Secretary who are at risk of opioid overdose may access 
     such opioid receptor antagonists and training on the proper 
     administration of such opioid receptor antagonists.
       (C) Veterans who are at risk.--For purposes of subparagraph 
     (B), veterans who are at risk of opioid overdose include--
       (i) veterans receiving long-term opioid therapy;
       (ii) veterans receiving opioid therapy who have a history 
     of substance use disorder or prior instances of overdose; and
       (iii) veterans who are at risk as determined by a health 
     care provider who is treating the veteran.
       (2) Report.--Not later than 120 days after the date of the 
     enactment of this Act, the Secretary shall submit to the 
     Committee on Veterans' Affairs of the Senate and the 
     Committee on Veterans' Affairs of the House of 
     Representatives a report on carrying out paragraph (1), 
     including an assessment of any remaining steps to be carried 
     out by the Secretary to carry out such paragraph.
       (f) Inclusion of Certain Information and Capabilities in 
     Opioid Therapy Risk Report Tool of the Department.--
       (1) Information.--The Secretary shall include in the Opioid 
     Therapy Risk Report tool of the Department--
       (A) information on the most recent time the tool was 
     accessed by a health care provider of the Department with 
     respect to each veteran; and
       (B) information on the results of the most recent urine 
     drug test for each veteran.
       (2) Capabilities.--The Secretary shall include in the 
     Opioid Therapy Risk Report tool the ability of the health 
     care providers of the Department to determine whether a 
     health care provider of the Department prescribed opioids to 
     a veteran without checking the information in the tool with 
     respect to the veteran.
       (g) Notifications of Risk in Computerized Health Record.--
     The Secretary shall modify the computerized patient record 
     system of the Department to ensure that any health care 
     provider that accesses the record of a veteran, regardless of 
     the reason the veteran seeks care

[[Page H2360]]

     from the health care provider, will be immediately notified 
     whether the veteran--
       (1) is receiving opioid therapy and has a history of 
     substance use disorder or prior instances of overdose;
       (2) has a history of opioid abuse; or
       (3) is at risk of becoming an opioid abuser as determined 
     by a health care provider who is treating the veteran.
       (h) Definitions.--In this section:
       (1) The term ``controlled substance'' has the meaning given 
     that term in section 102 of the Controlled Substances Act (21 
     U.S.C. 802).
       (2) The term ``State'' means each of the several States, 
     territories, and possessions of the United States, the 
     District of Columbia, and the Commonwealth of Puerto Rico.

     SEC. 303. STRENGTHENING OF JOINT WORKING GROUP ON PAIN 
                   MANAGEMENT OF THE DEPARTMENT OF VETERANS 
                   AFFAIRS AND THE DEPARTMENT OF DEFENSE.

       (a) In General.--Not later than 90 days after the date of 
     enactment of this Act, the Secretary of Veterans Affairs and 
     the Secretary of Defense shall ensure that the Pain 
     Management Working Group of the Health Executive Committee of 
     the Department of Veterans Affairs-Department of Defense 
     Joint Executive Committee (Pain Management Working Group) 
     established under section 320 of title 38, United States 
     Code, includes a focus on the following:
       (1) The opioid prescribing practices of health care 
     providers of each Department.
       (2) The ability of each Department to manage acute and 
     chronic pain among individuals receiving health care from the 
     Department, including training health care providers with 
     respect to pain management.
       (3) The use by each Department of complementary and 
     integrative health and complementary alternative medicines in 
     treating such individuals.
       (4) The concurrent use by health care providers of each 
     Department of opioids and prescription drugs to treat mental 
     health disorders, including benzodiazepines.
       (5) The practice by health care providers of each 
     Department of prescribing opioids to treat mental health 
     disorders.
       (6) The coordination in coverage of and consistent access 
     to medications prescribed for patients transitioning from 
     receiving health care from the Department of Defense to 
     receiving health care from the Department of Veterans 
     Affairs.
       (7) The ability of each Department to identify and treat 
     substance use disorders among individuals receiving health 
     care from that Department.
       (b) Coordination and Consultation.--The Secretary of 
     Veterans Affairs and the Secretary of Defense shall ensure 
     that the working group described in subsection (a)--
       (1) coordinates the activities of the working group with 
     other relevant working groups established under section 320 
     of title 38, United States Code;
       (2) consults with other relevant Federal agencies with 
     respect to the activities of the working group; and
       (3) consults with the Department of Veterans Affairs and 
     the Department of Defense with respect to, reviews, and 
     comments on the VA/DOD Clinical Practice Guideline for 
     Management of Opioid Therapy for Chronic Pain, or any 
     successor guideline, before any update to the guideline is 
     released.
       (c) Clinical Practice Guidelines.--
       (1) In general.--Not later than 180 days after the date of 
     the enactment of this Act, the Secretary of Veterans Affairs 
     and the Secretary of Defense shall issue an update to the VA/
     DOD Clinical Practice Guideline for Management of Opioid 
     Therapy for Chronic Pain.
       (2) Matters included.--In conducting the update under 
     subsection (a), the Pain Management Working Group, in 
     coordination with the Clinical Practice Guideline VA/DOD 
     Management of Opioid Therapy for Chronic Pain Working Group, 
     shall examine whether the Clinical Practical Guideline should 
     include the following:
       (A) Enhanced guidance with respect to--
       (i) the coadministration of an opioid and other drugs, 
     including benzodiazepines, that may result in life-limiting 
     drug interactions;
       (ii) the treatment of patients with current acute 
     psychiatric instability or substance use disorder or patients 
     at risk of suicide; and
       (iii) the use of opioid therapy to treat mental health 
     disorders other than opioid use disorder.
       (B) Enhanced guidance with respect to the treatment of 
     patients with behaviors or comorbidities, such as post-
     traumatic stress disorder or other psychiatric disorders, or 
     a history of substance abuse or addiction, that requires a 
     consultation or comanagement of opioid therapy with one or 
     more specialists in pain management, mental health, or 
     addictions.
       (C) Enhanced guidance with respect to health care 
     providers--
       (i) conducting an effective assessment for patients 
     beginning or continuing opioid therapy, including 
     understanding and setting realistic goals with respect to 
     achieving and maintaining an expected level of pain relief, 
     improved function, or a clinically appropriate combination of 
     both; and
       (ii) effectively assessing whether opioid therapy is 
     achieving or maintaining the established treatment goals of 
     the patient or whether the patient and health care provider 
     should discuss adjusting, augmenting, or discontinuing the 
     opioid therapy.
       (D) Guidelines to govern the methodologies used by health 
     care providers of the Department of Veterans Affairs and the 
     Department of Defense to taper opioid therapy when adjusting 
     or discontinuing the use of opioid therapy.
       (E) Guidelines with respect to appropriate case management 
     for patients receiving opioid therapy who transition between 
     inpatient and outpatient health care settings, which may 
     include the use of care transition plans.
       (F) Guidelines with respect to appropriate case management 
     for patients receiving opioid therapy who transition from 
     receiving care during active duty to post-military health 
     care networks.
       (G) Guidelines with respect to providing options, before 
     initiating opioid therapy, for pain management therapies 
     without the use of opioids and options to augment opioid 
     therapy with other clinical and complementary and integrative 
     health services to minimize opioid dependence.
       (H) Guidelines with respect to the provision of evidence-
     based non-opioid treatments within the Department of Veterans 
     Affairs and the Department of Defense, including medical 
     devices and other therapies approved or cleared by the Food 
     and Drug Administration for the treatment of chronic pain as 
     an alternative to or to augment opioid therapy.

     SEC. 304. REVIEW, INVESTIGATION, AND REPORT ON USE OF OPIOIDS 
                   IN TREATMENT BY DEPARTMENT OF VETERANS AFFAIRS.

       (a) Comptroller General Report.--
       (1) In general.--Not later than 2 years after the date of 
     the enactment of this Act, the Comptroller General of the 
     United States shall submit to the Committee on Veterans' 
     Affairs of the Senate and the Committee on Veterans' Affairs 
     of the House of Representatives a report on the Opioid Safety 
     Initiative of the Department of Veterans Affairs and the 
     opioid prescribing practices of health care providers of the 
     Department.
       (2) Elements.--The report submitted under paragraph (1) 
     shall include the following:
       (A) Recommendations on such improvements to the Opioid 
     Safety Initiative of the Department as the Comptroller 
     General considers appropriate.
       (B) Information with respect to--
       (i) deaths resulting from sentinel events involving 
     veterans prescribed opioids by a health care provider of the 
     Department;
       (ii) overall prescription rates and prescriptions 
     indications of opioids to treat non-cancer, non-palliative, 
     and non-hospice care patients;
       (iii) the prescription rates and prescriptions indications 
     of benzodiazepines and opioids concomitantly by health care 
     providers of the Department;
       (iv) the practice by health care providers of the 
     Department of prescribing opioids to treat patients without 
     any pain, including to treat patients with mental health 
     disorders other than opioid use disorder; and
       (v) the effectiveness of opioid therapy for patients 
     receiving such therapy, including the effectiveness of long-
     term opioid therapy.
       (C) An evaluation of processes of the Department in place 
     to oversee opioid use among veterans, including procedures to 
     identify and remedy potential over-prescribing of opioids by 
     health care providers of the Department.
       (D) An assessment of the implementation by the Secretary of 
     the VA/DOD Clinical Practice Guideline for Management of 
     Opioid Therapy for Chronic Pain.
       (b) Quarterly Progress Report on Implementation of 
     Comptroller General Recommendations.--Not later than 2 years 
     after the date of the enactment of this Act, and not later 
     than 30 days after the end of each quarter thereafter, the 
     Secretary of Veterans Affairs shall submit to the Committee 
     on Veterans' Affairs of the Senate and the Committee on 
     Veterans' Affairs of the House of Representatives a progress 
     report detailing the actions by the Secretary during the 
     period covered by the report to address any outstanding 
     findings and recommendations by the Comptroller General of 
     the United States under subsection (a) with respect to the 
     Veterans Health Administration.
       (c) Annual Review of Prescription Rates.--Not later than 1 
     year after the date of the enactment of this Act, and not 
     less frequently than annually for the following 5 years, the 
     Secretary shall submit to the Committee on Veterans' Affairs 
     of the Senate and the Committee on Veterans' Affairs of the 
     House of Representatives a report, with respect to each 
     medical facility of the Department of Veterans Affairs, to 
     collect and review information on opioids prescribed by 
     health care providers at the facility to treat non-cancer, 
     non-palliative, and non-hospice care patients that contains, 
     for the 1-year period preceding the submission of the report, 
     the following:
       (1) The number of patients and the percentage of the 
     patient population of the Department who were prescribed 
     benzodiazepines and opioids concurrently by a health care 
     provider of the Department.
       (2) The number of patients and the percentage of the 
     patient population of the Department without any pain who 
     were prescribed opioids by a health care provider of the 
     Department, including those who were prescribed 
     benzodiazepines and opioids concurrently.
       (3) The number of non-cancer, non-palliative, and non-
     hospice care patients and the percentage of such patients who 
     were treated with opioids by a health care provider of the 
     Department on an inpatient-basis and who also received 
     prescription opioids by mail from the Department while being 
     treated on an inpatient-basis.
       (4) The number of non-cancer, non-palliative, and non-
     hospice care patients and the percentage of such patients who 
     were prescribed opioids concurrently by a health care 
     provider of the Department and a health care provider that is 
     not health care provider of the Department.
       (5) With respect to each medical facility of the 
     Department, information on opioids prescribed by health care 
     providers at the facility to treat non-cancer, non-
     palliative, and non-hospice care patients, including 
     information on--

[[Page H2361]]

       (A) the prescription rate at which each health care 
     provider at the facility prescribed benzodiazepines and 
     opioids concurrently to such patients and the aggregate such 
     prescription rate for all health care providers at the 
     facility;
       (B) the prescription rate at which each health care 
     provider at the facility prescribed benzodiazepines or 
     opioids to such patients to treat conditions for which 
     benzodiazepines or opioids are not approved treatment and the 
     aggregate such prescription rate for all health care 
     providers at the facility;
       (C) the prescription rate at which each health care 
     provider at the facility prescribed or dispensed mail-order 
     prescriptions of opioids to such patients while such patients 
     were being treated with opioids on an inpatient-basis and the 
     aggregate of such prescription rate for all health care 
     providers at the facility; and
       (D) the prescription rate at which each health care 
     provider at the facility prescribed opioids to such patients 
     who were also concurrently prescribed opioids by a health 
     care provider that is not a health care provider of the 
     Department and the aggregate of such prescription rates for 
     all health care providers at the facility.
       (6) With respect to each medical facility of the 
     Department, the number of times a pharmacist at the facility 
     overrode a critical drug interaction warning with respect to 
     an interaction between opioids and another medication before 
     dispensing such medication to a veteran.
       (d) Investigation of Prescription Rates.--If the Secretary 
     determines that a prescription rate with respect to a health 
     care provider or medical facility of the Department conflicts 
     with or is otherwise inconsistent with the standards of 
     appropriate and safe care, the Secretary shall--
       (1) immediately notify the Committee on Veterans' Affairs 
     of the Senate and the Committee on Veterans' Affairs of the 
     House of Representatives of such determination, including 
     information relating to such determination, prescription 
     rate, and health care provider or medical facility, as the 
     case may be; and
       (2) through the Office of the Medical Inspector of the 
     Veterans Health Administration, conduct a full investigation 
     of the health care provider or medical facility, as the case 
     may be.
       (e) Prescription Rate Defined.--In this section, the term 
     ``prescription rate'' means, with respect to a health care 
     provider or medical facility of the Department, each of the 
     following:
       (1) The number of patients treated with opioids by the 
     health care provider or at the medical facility, as the case 
     may be, divided by the total number of pharmacy users of that 
     health care provider or medical facility.
       (2) The average number of morphine equivalents per day 
     prescribed by the health care provider or at the medical 
     facility, as the case may be, to patients being treated with 
     opioids.
       (3) Of the patients being treated with opioids by the 
     health care provider or at the medical facility, as the case 
     may be, the average number of prescriptions of opioids per 
     patient.

     SEC. 305. MANDATORY DISCLOSURE OF CERTAIN VETERAN INFORMATION 
                   TO STATE CONTROLLED SUBSTANCE MONITORING 
                   PROGRAMS.

       Section 5701(l) of title 38, United States Code, is amended 
     by striking ``may'' and inserting ``shall''.

     SEC. 306. MODIFICATION TO LIMITATION ON AWARDS AND BONUSES.

       Section 705 of the Veterans Access, Choice, and 
     Accountability Act of 2014 (Public Law 113-146; 38 U.S.C. 703 
     note) is amended to read as follows:

     ``SEC. 705. LIMITATION ON AWARDS AND BONUSES PAID TO 
                   EMPLOYEES OF DEPARTMENT OF VETERANS AFFAIRS.

       ``The Secretary of Veterans Affairs shall ensure that the 
     aggregate amount of awards and bonuses paid by the Secretary 
     in a fiscal year under chapter 45 or 53 of title 5, United 
     States Code, or any other awards or bonuses authorized under 
     such title or title 38, United States Code, does not exceed 
     the following amounts:
       ``(1) With respect to each of fiscal years 2017 through 
     2021, $230,000,000.
       ``(2) With respect to each of fiscal years 2022 through 
     2024, $360,000,000.''.

             TITLE IV--KINGPIN DESIGNATION IMPROVEMENT ACT

     SEC. 401. SHORT TITLE.

       This title may be cited as the ``Kingpin Designation 
     Improvement Act of 2016''.

     SEC. 402. PROTECTION OF CLASSIFIED INFORMATION IN FEDERAL 
                   COURT CHALLENGES RELATING TO DESIGNATIONS UNDER 
                   THE NARCOTICS KINGPIN DESIGNATION ACT.

       Section 804 of the Foreign Narcotics Kingpin Designation 
     Act (21 U.S.C. 1903) is amended by adding at the end the 
     following:
       ``(i) Protection of Classified Information in Federal Court 
     Challenges Relating to Designations.--In any judicial review 
     of a determination made under this section, if the 
     determination was based on classified information (as defined 
     in section 1(a) of the Classified Information Procedures Act) 
     such information may be submitted to the reviewing court ex 
     parte and in camera. This subsection does not confer or imply 
     any right to judicial review.''.

                 TITLE V--GOOD SAMARITAN ASSESSMENT ACT

     SEC. 501. SHORT TITLE.

       This title may be cited as the ``Good Samaritan Assessment 
     Act of 2016''.

     SEC. 502. FINDING.

       The Congress finds that the executive branch, including the 
     Office of National Drug Control Policy, has a policy focus on 
     preventing and addressing prescription drug misuse and heroin 
     use, and has worked with States and municipalities to enact 
     Good Samaritan laws that would protect caregivers, law 
     enforcement personnel, and first responders who administer 
     opioid overdose reversal drugs or devices.

     SEC. 503. GAO STUDY ON GOOD SAMARITAN LAWS PERTAINING TO 
                   TREATMENT OF OPIOID OVERDOSES.

       The Comptroller General of the United States shall submit 
     to the Committee on the Judiciary of the House of 
     Representatives, the Committee on Oversight and Government 
     Reform of the House of Representatives, the Committee on the 
     Judiciary of the Senate, and the Committee on Homeland 
     Security and Governmental Affairs of the Senate a report on--
       (1) the extent to which the Director of National Drug 
     Control Policy has reviewed Good Samaritan laws, and any 
     findings from such a review, including findings related to 
     the potential effects of such laws, if available;
       (2) efforts by the Director to encourage the enactment of 
     Good Samaritan laws; and
       (3) a compilation of Good Samaritan laws in effect in the 
     States, the territories, and the District of Columbia.

     SEC. 504. DEFINITIONS.

       In this title--
       (1) the term ``Good Samaritan law'' means a law of a State 
     or unit of local government that exempts from criminal or 
     civil liability any individual who administers an opioid 
     overdose reversal drug or device, or who contacts emergency 
     services providers in response to an overdose; and
       (2) the term ``opioid'' means any drug, including heroin, 
     having an addiction-forming or addiction-sustaining liability 
     similar to morphine or being capable of conversion into a 
     drug having such addiction-forming or addiction-sustaining 
     liability.

                           TITLE VI--OPEN ACT

     SEC. 601. SHORT TITLE.

       This title may be cited as the ``Opioid Program Evaluation 
     Act'' or the ``OPEN Act''.

     SEC. 602. EVALUATION OF PERFORMANCE OF DEPARTMENT OF JUSTICE 
                   PROGRAM.

       (a) Evaluation of Justice Department Comprehensive Opioid 
     Abuse Grant Program.--Not later than 5 years after the date 
     of enactment of this Act, the Attorney General shall complete 
     an evaluation of the effectiveness of the Comprehensive 
     Opioid Abuse Grant Program under part LL of the Omnibus Crime 
     Control and Safe Streets Act of 1968 administered by the 
     Department of Justice based upon the information reported 
     under subsection (d) of this section.
       (b) Interim Evaluation.--Not later than 3 years after the 
     date of enactment of this Act, the Attorney General shall 
     complete an interim evaluation assessing the nature and 
     extent of the incidence of opioid abuse and illegal opioid 
     distribution in the United States.
       (c) Metrics and Outcomes for Evaluation.--Not later than 
     180 days after the date of enactment of this Act, the 
     Attorney General shall identify outcomes that are to be 
     achieved by activities funded by the Comprehensive Opioid 
     Grant Abuse Program and the metrics by which the achievement 
     of such outcomes shall be determined.
       (d) Metrics Data Collection.--The Attorney General shall 
     require grantees under the Comprehensive Opioid Abuse Grant 
     Program (and those receiving subawards under section 3021(b) 
     of part LL of the Omnibus Crime Control and Safe Streets Act 
     of 1968) to collect and annually report to the Department of 
     Justice data based upon the metrics identified under 
     subsection (c).
       (e) Publication of Data and Findings.--
       (1) Publication of outcomes and metrics.--The Attorney 
     General shall, not later than 30 days after completion of the 
     requirement under subsection (c), publish the outcomes and 
     metrics identified under that subsection.
       (2) Publication of evaluation.--In the case of the interim 
     evaluation under subsection (b), and the final evaluation 
     under subsection (a), the National Academy of Sciences shall, 
     not later than 90 days after such an evaluation is completed, 
     publish the results of such evaluation and issue a report on 
     such evaluation to the Committee on the Judiciary of the 
     House of Representatives and the Committee on the Judiciary 
     of the Senate. Such report shall also be published along with 
     the data used to make such evaluation.
       (f) Arrangement With the National Academy of Sciences.--For 
     purposes of subsections (a), (b), and (c), the Attorney 
     General shall enter into an arrangement with the National 
     Academy of Sciences.

     SEC. 603. EVALUATION OF PERFORMANCE OF DEPARTMENT OF HEALTH 
                   AND HUMAN SERVICES PROGRAM.

       (a) Evaluation of Department of Health and Human Services 
     Programs.--Not later than 5 years after the date of enactment 
     of this Act, except as otherwise provided in this section, 
     the Secretary of Health and Human Services shall complete an 
     evaluation of any program administered by the Secretary that 
     provides grants for the primary purpose of providing 
     assistance in addressing problems pertaining to opioid abuse 
     based upon the information reported under subsection (d) of 
     this section.
       (b) Interim Evaluation.--Not later than 3 years after the 
     date of enactment of this Act, the Secretary shall complete 
     an interim evaluation assessing the nature and extent of the 
     incidence of opioid abuse and illegal opioid distribution in 
     the United States.
       (c) Metrics and Outcomes for Evaluation.--Not later than 
     180 days after the date of enactment of this Act, the 
     Secretary shall identify outcomes that are to be achieved by 
     activities funded by the programs described in subsection (a) 
     and the metrics by which the achievement of such outcomes 
     shall be determined.
       (d) Metrics Data Collection.--The Secretary shall require 
     grantees under the programs

[[Page H2362]]

     described in subsection (a) to collect and annually report to 
     the Department of Health and Human Services data based upon 
     the metrics identified under subsection (c).
       (e) Publication of Data and Findings.--
       (1) Publication of outcomes and metrics.--The Secretary 
     shall, not later than 30 days after completion of the 
     requirement under subsection (c), publish the outcomes and 
     metrics identified under that subsection.
       (2) Publication of evaluation.--In the case of the interim 
     evaluation under subsection (b), and each final evaluation 
     under subsection (a), the National Academy of Sciences shall, 
     not later than 90 days after such an evaluation is completed, 
     publish the results of such evaluation and issue a report on 
     such evaluation to the Committee on Energy and Commerce of 
     the House of Representatives and the Committee on Health, 
     Education, Labor, and Pensions of the Senate. Such report 
     shall also be published along with the data used to make such 
     evaluation.
       (f) Arrangement With the National Academy of Sciences.--For 
     purposes of subsections (a), (b), and (c), the Secretary 
     shall--
       (1) enter into an arrangement with the National Academy of 
     Sciences; or
       (2) enter into a contract or cooperative agreement with an 
     entity that is not an agency of the Federal Government.
       (g) Exception.--If a program described under subsection (a) 
     is subject to an evaluation substantially similar to the 
     evaluation under subsection (a) pursuant to another provision 
     of law, the Secretary may opt not to conduct an evaluation 
     under subsection (a) of such program.

     SEC. 604. DEFINITION.

       In this title, the term ``opioid'' has the meaning given 
     the term ``opiate'' in section 102 of the Controlled 
     Substances Act (21 U.S.C. 802).

     SEC. 605. NO ADDITIONAL FUNDS AUTHORIZED.

       No additional funds are authorized to be appropriated to 
     carry out this Act.

     SEC. 606. MATTERS REGARDING CERTAIN FEDERAL LAW ENFORCEMENT 
                   ASSISTANCE.

       Section 609Y of the Justice Assistance Act of 1984 (42 
     U.S.C. 10513) is amended--
       (1) in subsection (a), by striking ``There is'' and 
     inserting ``Except as provided in subsection (c), there is''; 
     and
       (2) by adding at the end the following:
       ``(c) For fiscal year 2022, there is authorized to be 
     appropriated $16,000,000, to provide under this chapter 
     Federal law enforcement assistance in the form of funds.''.

          TITLE VII--INFANT PLAN OF SAFE CARE IMPROVEMENT ACT

     SEC. 701. SHORT TITLE.

       This title may be cited as the ``Infant Plan of Safe Care 
     Improvement Act''.

     SEC. 702. BEST PRACTICES FOR DEVELOPMENT OF PLANS OF SAFE 
                   CARE.

       Section 103(b) of the Child Abuse Prevention and Treatment 
     Act (42 U.S.C. 5104(b)) is amended--
       (1) by redesignating paragraphs (5) through (8) as 
     paragraphs (6) through (9), respectively; and
       (2) by inserting after paragraph (4), the following:
       ``(5) maintain and disseminate information about the 
     requirements of section 106(b)(2)(B)(iii) and best practices 
     relating to the development of plans of safe care as 
     described in such section for infants born and identified as 
     being affected by illegal substance abuse or withdrawal 
     symptoms, or a Fetal Alcohol Spectrum Disorder;''.

     SEC. 703. STATE PLANS.

       Section 106(b)(2)(B)(iii) of the Child Abuse Prevention and 
     Treatment Act (42 U.S.C. 5106a(b)(2)(B)(iii)) is amended by 
     inserting before the semicolon at the end the following: ``to 
     ensure the safety and well-being of such infant following 
     release from the care of healthcare providers, including 
     through--''

       ``(I) addressing the health and substance use disorder 
     treatment needs of the infant and affected family or 
     caregiver; and
       ``(II) the development and implementation by the State of 
     monitoring systems regarding the implementation of such plans 
     to determine whether and in what manner local entities are 
     providing, in accordance with State requirements, referrals 
     to and delivery of appropriate services for the infant and 
     affected family or caregiver''.

     SEC. 704. DATA REPORTS.

       (a) In General.--Section 106(d) of the Child Abuse 
     Prevention and Treatment Act (42 U.S.C. 5106a(d)) is amended 
     by adding at the end of the following:
       ``(17)(A) The number of infants identified under subsection 
     (b)(2)(B)(ii).
       ``(B) The number of infants for whom a plan of safe care 
     was developed under subsection (b)(2)(B)(iii).
       ``(C) The number of infants for whom a referral was made 
     for appropriate services, including services for the affected 
     family or caregiver, under subsection (b)(2)(B)(iii).''.
       (b) Redesignation.--Effective on May 29, 2017, section 
     106(d) of the Child Abuse Prevention and Treatment Act (42 
     U.S.C. 5106a(d)) is amended by redesignating paragraph (17) 
     (as added by subsection (a)) as paragraph (18).

     SEC. 705. MONITORING AND OVERSIGHT.

       (a) Amendment.--Title I of the Child Abuse Prevention and 
     Treatment Act (42 U.S.C. 5101 et seq.) is further amended by 
     adding at the end the following:

     ``SEC. 114. MONITORING AND OVERSIGHT.

       ``The Secretary shall conduct monitoring to ensure that 
     each State that receives a grant under section 106 is in 
     compliance with the requirements of section 106(b), which--
       ``(1) shall--
       ``(A) be in addition to the review of the State plan upon 
     its submission under section 106(b)(1)(A); and
       ``(B) include monitoring of State policies and procedures 
     required under clauses (ii) and (iii) of section 
     106(b)(2)(B); and
       ``(2) may include--
       ``(A) a comparison of activities carried out by the State 
     to comply with the requirements of section 106(b) with the 
     State plan most recently approved under section 432 of the 
     Social Security Act;
       ``(B) a review of information available on the Website of 
     the State relating to its compliance with the requirements of 
     section 106(b);
       ``(C) site visits, as may be necessary to carry out such 
     monitoring; and
       ``(D) a review of information available in the State's 
     Annual Progress and Services Report most recently submitted 
     under section 1357.16 of title 45, Code of Federal 
     Regulations (or successor regulations).''.
       (b) Table of Contents.--The table of contents in section 
     1(b) of the Child Abuse Prevention and Treatment Act (42 
     U.S.C. 5101 note) is amended by inserting after the item 
     relating to section 113, the following:

``Sec. 114. Monitoring and oversight.''.

     SEC. 706. RULE OF CONSTRUCTION.

       Nothing in this Act, or the amendments made by this Act, 
     shall be construed to authorize the Secretary of Health and 
     Human Services or any other officer of the Federal Government 
     to add new requirements to section 106(b) of the Child Abuse 
     Prevention and Treatment Act (42 U.S.C. 5106a(b)), as amended 
     by this Act.

                   TITLE VIII--NAS HEALTHY BABIES ACT

     SEC. 801. SHORT TITLE.

       This title may be cited as the ``Nurturing And Supporting 
     Healthy Babies Act'' or as the ``NAS Healthy Babies Act''.

     SEC. 802. GAO REPORT ON NEONATAL ABSTINENCE SYNDROME (NAS).

       (a) In General.--Not later than 1 year after the date of 
     the enactment of this Act, the Comptroller General of the 
     United States shall submit to the Committee on Energy and 
     Commerce of the House of Representatives and the Committee on 
     Finance and the Committee on Health, Education, Labor and 
     Pensions of the Senate a report on neonatal abstinence 
     syndrome (in this section referred to as ``NAS'') in the 
     United States.
       (b) Information To Be Included in Report.--Such report 
     shall include information on the following:
       (1) The prevalence of NAS in the United States, including 
     the proportion of children born in the United States with NAS 
     who are eligible for medical assistance under State Medicaid 
     programs under title XIX of the Social Security Act at birth 
     and the costs associated with NAS through such programs.
       (2) The services for which coverage is available under 
     State Medicaid programs for treatment of infants with NAS.
       (3) The settings (including inpatient, outpatient, 
     hospital-based, and other settings) for the treatment of 
     infants with NAS and the reimbursement methodologies and 
     costs associated with such treatment in such settings.
       (4) The prevalence of utilization of various care settings 
     under State Medicaid programs for treatment of infants with 
     NAS and any Federal barriers to treating such infants under 
     such programs, particularly in non-hospital-based settings.
       (5) What is known about best practices for treating infants 
     with NAS.
       (c) Recommendations.--Such report also shall include such 
     recommendations as the Comptroller General determines 
     appropriate for improvements that will ensure access to 
     treatment for infants with NAS under State Medicaid programs.

     SEC. 803. EXCLUDING ABUSE-DETERRENT FORMULATIONS OF 
                   PRESCRIPTION DRUGS FROM THE MEDICAID ADDITIONAL 
                   REBATE REQUIREMENT FOR NEW FORMULATIONS OF 
                   PRESCRIPTION DRUGS.

       (a) In General.--The last sentence of section 1927(c)(2)(C) 
     of the Social Security Act (42 U.S.C. 1396r-8(c)(2)(C)) is 
     amended by inserting before the period at the end the 
     following: ``, but does not include an abuse-deterrent 
     formulation of the drug (as determined by the Secretary), 
     regardless of whether such abuse-deterrent formulation is an 
     extended release formulation''.
       (b) Effective Date.--The amendment made by subsection (a) 
     shall apply to drugs that are paid for by a State in calendar 
     quarters beginning on or after the date of the enactment of 
     this Act.

     SEC. 804. LIMITING DISCLOSURE OF PREDICTIVE MODELING AND 
                   OTHER ANALYTICS TECHNOLOGIES TO IDENTIFY AND 
                   PREVENT WASTE, FRAUD, AND ABUSE.

       (a) In General.--Title XI of the Social Security Act is 
     amended by inserting after section 1128J (42 U.S.C. 1320a-7k) 
     the following new section:

     ``SEC. 1128K. DISCLOSURE OF PREDICTIVE MODELING AND OTHER 
                   ANALYTICS TECHNOLOGIES TO IDENTIFY AND PREVENT 
                   WASTE, FRAUD, AND ABUSE.

       ``(a) Reference to Predictive Modeling Technologies 
     Requirements.--For provisions relating to the use of 
     predictive modeling and other analytics technologies to 
     identify and prevent waste, fraud, and abuse with respect to 
     the Medicare program under title XVIII, the Medicaid program 
     under title XIX, and the Children's Health Insurance Program 
     under title XXI, see section 4241 of the Small Business Jobs 
     Act of 2010 (42 U.S.C. 1320a-7m).
       ``(b) Limiting Disclosure of Predictive Modeling 
     Technologies.--In implementing

[[Page H2363]]

     such provisions under such section 4241 with respect to 
     covered algorithms (as defined in subsection (c)), the 
     following shall apply:
       ``(1) Nonapplication of foia.--The covered algorithms used 
     or developed for purposes of such section (including by the 
     Secretary or a State (or an entity operating under a contract 
     with a State)) shall be exempt from disclosure under section 
     552(b)(3) of title 5, United States Code.
       ``(2) Limitation with respect to use and disclosure of 
     information by state agencies.--
       ``(A) In general.--A State agency may not use or disclose 
     covered algorithms used or developed for purposes of such 
     section except for purposes of administering the State plan 
     (or a waiver of the plan) under the Medicaid program under 
     title XIX or the State child health plan (or a waiver of the 
     plan) under the Children's Health Insurance Program under 
     title XXI, including by enabling an entity operating under a 
     contract with a State to assist the State to identify or 
     prevent waste, fraud, and abuse with respect to such 
     programs.
       ``(B) Information security.--A State agency shall have in 
     effect data security and control policies that the Secretary 
     finds adequate to ensure the security of covered algorithms 
     used or developed for purposes of such section 4241 and to 
     ensure that access to such information is restricted to 
     authorized persons for purposes of authorized uses and 
     disclosures described in subparagraph (A).
       ``(C) Procedural requirements.--State agencies to which 
     information is disclosed pursuant to such section 4241 shall 
     adhere to uniform procedures established by the Secretary.
       ``(c) Covered Algorithm Defined.--In this section, the term 
     `covered algorithm'--
       ``(1) means a predictive modeling or other analytics 
     technology, as used for purposes of section 4241(a) of the 
     Small Business Jobs Act of 2010 (42 U.S.C. 1320a-7m(a)) to 
     identify and prevent waste, fraud, and abuse with respect to 
     the Medicare program under title XVIII, the Medicaid program 
     under title XIX, and the Children's Health Insurance Program 
     under title XXI; and
       ``(2) includes the mathematical expressions utilized in the 
     application of such technology and the means by which such 
     technology is developed.''.
       (b) Conforming Amendments.--
       (1) Medicaid state plan requirement.--Section 1902(a) of 
     the Social Security Act (42 U.S.C. 1396a(a)) is amended--
       (A) in paragraph (80), by striking ``and'' at the end;
       (B) in paragraph (81), by striking the period at the end 
     and inserting ``; and''; and
       (C) by inserting after paragraph (81) the following new 
     paragraph:
       ``(82) provide that the State agency responsible for 
     administering the State plan under this title provides 
     assurances to the Secretary that the State agency is in 
     compliance with subparagraphs (A), (B), and (C) of section 
     1128K(b)(2).''.
       (2) State child health plan requirement.--Section 
     2102(a)(7) of the Social Security Act (42 U.S.C. 
     1397bb(a)(7)) is amended--
       (A) in subparagraph (A), by striking ``, and'' at the end 
     and inserting a semicolon;
       (B) in subparagraph (B), by striking the period at the end 
     and inserting ``; and''; and
       (C) by adding at the end the following new subparagraph:
       ``(C) to ensure that the State agency involved is in 
     compliance with subparagraphs (A), (B), and (C) of section 
     1128K(b)(2).''.

     SEC. 805. MEDICAID IMPROVEMENT FUND.

       Section 1941(b)(1) of the Social Security Act (42 U.S.C. 
     1396w-1(b)(1)) is amended to read as follows:
       ``(1) In general.--There shall be available to the Fund, 
     for expenditures from the Fund for fiscal year 2021 and 
     thereafter, $5,000,000.''.

            TITLE IX--CO-PRESCRIBING TO REDUCE OVERDOSES ACT

     SEC. 901. SHORT TITLE.

       This title may be cited as the ``Co-Prescribing to Reduce 
     Overdoses Act of 2016''.

     SEC. 902. OPIOID OVERDOSE REVERSAL DRUGS PRESCRIBING GRANT 
                   PROGRAM.

       (a) Establishment.--
       (1) In general.--Not later than 6 months after the date of 
     the enactment of this Act, the Secretary of Health and Human 
     Services may establish, in accordance with this section, a 5-
     year opioid overdose reversal drugs prescribing grant program 
     (in this Act referred to as the ``grant program'').
       (2) Maximum grant amount.--A grant made under this section 
     may not be for more than $200,000 per grant year.
       (3) Eligible entity.--For purposes of this section, the 
     term ``eligible entity'' means a federally qualified health 
     center (as defined in section 1861(aa) of the Social Security 
     Act (42 U.S.C. 1395x(aa)), an opioid treatment program under 
     part 8 of title 42, Code of Federal Regulations, any 
     practitioner dispensing narcotic drugs pursuant to section 
     303(g) of the Controlled Substances Act (21 U.S.C. 823(g)), 
     or any other entity that the Secretary deems appropriate.
       (4) Prescribing.--For purposes of this section and section 
     3, the term ``prescribing'' means, with respect to an opioid 
     overdose reversal drug, such as naloxone, the practice of 
     prescribing such drug--
       (A) in conjunction with an opioid prescription for patients 
     at an elevated risk of overdose;
       (B) in conjunction with an opioid agonist approved under 
     section 505 of the Federal Food, Drug, and Cosmetic Act (21 
     U.S.C. 355) for the treatment of opioid abuse disorder;
       (C) to the caregiver or a close relative of patients at an 
     elevated risk of overdose from opioids; or
       (D) in other circumstances, as identified by the Secretary, 
     in which a provider identifies a patient is at an elevated 
     risk for an intentional or unintentional drug overdose from 
     heroin or prescription opioid therapies.
       (b) Application.--To be eligible to receive a grant under 
     this section, an eligible entity shall submit to the 
     Secretary of Health and Human Services, in such form and 
     manner as specified by the Secretary, an application that 
     describes--
       (1) the extent to which the area to which the entity will 
     furnish services through use of the grant is experiencing 
     significant morbidity and mortality caused by opioid abuse;
       (2) the criteria that will be used to identify eligible 
     patients to participate in such program; and
       (3) how such program will work to try to identify State, 
     local, or private funding to continue the program after 
     expiration of the grant.
       (c) Use of Funds.--An eligible entity receiving a grant 
     under this section may use the grant for any of the following 
     activities, but may use not more than 20 percent of the grant 
     funds for activities described in paragraphs (4) and (5):
       (1) To establish a program for prescribing opioid overdose 
     reversal drugs, such as naloxone.
       (2) To train and provide resources for health care 
     providers and pharmacists on the prescribing of opioid 
     overdose reversal drugs, such as naloxone.
       (3) To establish mechanisms and processes for tracking 
     patients participating in the program described in paragraph 
     (1) and the health outcomes of such patients.
       (4) To purchase opioid overdose reversal drugs, such as 
     naloxone, for distribution under the program described in 
     paragraph (1).
       (5) To offset the co-pays and other cost sharing associated 
     with opioid overdose reversal drugs, such as naloxone, to 
     ensure that cost is not a limiting factor for eligible 
     patients.
       (6) To conduct community outreach, in conjunction with 
     community-based organizations, designed to raise awareness of 
     prescribing practices, and the availability of opioid 
     overdose reversal drugs, such as naloxone.
       (7) To establish protocols to connect patients who have 
     experienced a drug overdose with appropriate treatment, 
     including medication assisted treatment and appropriate 
     counseling and behavioral therapies.
       (d) Evaluations by Recipients.--As a condition of receipt 
     of a grant under this section, an eligible entity shall, for 
     each year for which the grant is received, submit to the 
     Secretary of Health and Human Services information on 
     appropriate outcome measures specified by the Secretary to 
     assess the outcomes of the program funded by the grant, 
     including--
       (1) the number of prescribers trained;
       (2) the number of prescribers who have co-prescribed an 
     opioid overdose reversal drug, such as naloxone, to at least 
     one patient;
       (3) the total number of prescriptions written for opioid 
     overdose reversal drugs, such as naloxone;
       (4) the percentage of patients at elevated risk who 
     received a prescription for an opioid overdose reversal drug, 
     such as naloxone;
       (5) the number of patients reporting use of an opioid 
     overdose reversal drug, such as naloxone; and
       (6) any other outcome measures that the Secretary deems 
     appropriate.
       (e) Reports by Secretary.--For each year of the grant 
     program under this section, the Secretary of Health and Human 
     Services shall submit to the appropriate committees of the 
     House of Representatives and of the Senate a report 
     aggregating the information received from the grant 
     recipients for such year under subsection (d) and evaluating 
     the outcomes achieved by the programs funded by grants made 
     under this section.

     SEC. 903. PROVIDING INFORMATION TO PRESCRIBERS IN CERTAIN 
                   FEDERAL HEALTH CARE AND MEDICAL FACILITIES ON 
                   BEST PRACTICES FOR PRESCRIBING OPIOID OVERDOSE 
                   REVERSAL DRUGS.

       (a) In General.--Not later than 180 days after the date of 
     enactment of this Act, the Secretary of Health and Human 
     Services (in this section referred to as the ``Secretary'') 
     may, as appropriate, provide information to prescribers 
     within federally qualified health centers (as defined in 
     paragraph (4) of section 1861(aa) of the Social Security Act 
     (42 U.S.C. 1395x(aa))), and the health care facilities of the 
     Indian Health Service, on best practices for prescribing 
     opioid overdose reversal drugs, such as naloxone, for 
     patients receiving chronic opioid therapy, patients being 
     treated for opioid use disorders, and other patients that a 
     provider identifies as having an elevated risk of overdose 
     from heroin or prescription opioid therapies.
       (b) Not Establishing a Medical Standard of Care.--The 
     information on best practices provided under this section 
     shall not be construed as constituting or establishing a 
     medical standard of care for prescribing opioid overdose 
     reversal drugs, such as naloxone, for patients described in 
     subsection (a).
       (c) Elevated Risk of Overdose Defined.--In this section, 
     the term ``elevated risk of overdose'' has the meaning given 
     such term by the Secretary, which--
       (1) may be based on the criteria provided in the Opioid 
     Overdose Toolkit published by the Substance Abuse and Mental 
     Health Services Administration (SAMHSA); and
       (2) may include patients on a first course opioid 
     treatment, patients using extended-release and long-acting 
     opioid analgesics, and patients with a respiratory disease or 
     other co-morbidities.

     SEC. 904. AUTHORIZATION OF APPROPRIATIONS.

       There is authorized to be appropriated to carry out this 
     title $5,000,000 for the period of fiscal years 2017 through 
     2021.

[[Page H2364]]

  


     SEC. 905. CUT-GO COMPLIANCE.

       Subsection (f) of section 319D of the Public Health Service 
     Act (42 U.S.C. 247d-4) is amended by inserting before the 
     period at the end the following: ``(except such dollar amount 
     shall be reduced by $5,000,000 for fiscal year 2018)''.

   TITLE X--IMPROVING TREATMENT FOR PREGNANT AND POSTPARTUM WOMEN ACT

     SEC. 1001. SHORT TITLE.

       This title may be cited as the ``Improving Treatment for 
     Pregnant and Postpartum Women Act of 2016''.

     SEC. 1002. REAUTHORIZATION OF RESIDENTIAL TREATMENT PROGRAMS 
                   FOR PREGNANT AND POSTPARTUM WOMEN.

       Section 508 of the Public Health Service Act (42 U.S.C. 
     290bb-1) is amended--
       (1) in subsection (p), in the first sentence, by inserting 
     ``(other than subsection (r))'' after ``section''; and
       (2) in subsection (r), by striking ``such sums'' and all 
     that follows through ``2003'' and inserting ``$16,900,000 for 
     each of fiscal years 2017 through 2021''.

     SEC. 1003. PILOT PROGRAM GRANTS FOR STATE SUBSTANCE ABUSE 
                   AGENCIES.

       (a) In General.--Section 508 of the Public Health Service 
     Act (42 U.S.C. 290bb-1) is amended--
       (1) by redesignating subsection (r), as amended by section 
     2, as subsection (s); and
       (2) by inserting after subsection (q) the following new 
     subsection:
       ``(r) Pilot Program for State Substance Abuse Agencies.--
       ``(1) In general.--From amounts made available under 
     subsection (s), the Director of the Center for Substance 
     Abuse Treatment shall carry out a pilot program under which 
     competitive grants are made by the Director to State 
     substance abuse agencies to--
       ``(A) enhance flexibility in the use of funds designed to 
     support family-based services for pregnant and postpartum 
     women with a primary diagnosis of a substance use disorder, 
     including opioid use disorders;
       ``(B) help State substance abuse agencies address 
     identified gaps in services furnished to such women along the 
     continuum of care, including services provided to women in 
     nonresidential based settings; and
       ``(C) promote a coordinated, effective, and efficient State 
     system managed by State substance abuse agencies by 
     encouraging new approaches and models of service delivery.
       ``(2) Requirements.--In carrying out the pilot program 
     under this subsection, the Director shall--
       ``(A) require State substance abuse agencies to submit to 
     the Director applications, in such form and manner and 
     containing such information as specified by the Director, to 
     be eligible to receive a grant under the program;
       ``(B) identify, based on such submitted applications, State 
     substance abuse agencies that are eligible for such grants;
       ``(C) require services proposed to be furnished through 
     such a grant to support family-based treatment and other 
     services for pregnant and postpartum women with a primary 
     diagnosis of a substance use disorder, including opioid use 
     disorders;
       ``(D) not require that services furnished through such a 
     grant be provided solely to women that reside in facilities;
       ``(E) not require that grant recipients under the program 
     make available through use of the grant all services 
     described in subsection (d); and
       ``(F) consider not applying requirements described in 
     paragraphs (1) and (2) of subsection (f) to applicants, 
     depending on the circumstances of the applicant.
       ``(3) Required services.--
       ``(A) In general.--The Director shall specify a minimum set 
     of services required to be made available to eligible women 
     through a grant awarded under the pilot program under this 
     subsection. Such minimum set--
       ``(i) shall include requirements described in subsection 
     (c) and be based on the recommendations submitted under 
     subparagraph (B); and
       ``(ii) may be selected from among the services described in 
     subsection (d) and include other services as appropriate.
       ``(B) Stakeholder input.--The Director shall convene and 
     solicit recommendations from stakeholders, including State 
     substance abuse agencies, health care providers, persons in 
     recovery from substance abuse, and other appropriate 
     individuals, for the minimum set of services described in 
     subparagraph (A).
       ``(4) Duration.--The pilot program under this subsection 
     shall not exceed 5 years.
       ``(5) Evaluation and report to congress.--The Director of 
     the Center for Behavioral Health Statistics and Quality shall 
     fund an evaluation of the pilot program at the conclusion of 
     the first grant cycle funded by the pilot program. The 
     Director of the Center for Behavioral Health Statistics and 
     Quality, in coordination with the Director of the Center for 
     Substance Abuse Treatment shall submit to the relevant 
     committees of jurisdiction of the House of Representatives 
     and the Senate a report on such evaluation. The report shall 
     include at a minimum outcomes information from the pilot 
     program, including any resulting reductions in the use of 
     alcohol and other drugs; engagement in treatment services; 
     retention in the appropriate level and duration of services; 
     increased access to the use of medications approved by the 
     Food and Drug Administration for the treatment of substance 
     use disorders in combination with counseling; and other 
     appropriate measures.
       ``(6) State substance abuse agencies defined.--For purposes 
     of this subsection, the term `State substance abuse agency' 
     means, with respect to a State, the agency in such State that 
     manages the Substance Abuse Prevention and Treatment Block 
     Grant under part B of title XIX.''.
       (b) Funding.--Subsection (s) of section 508 of the Public 
     Health Service Act (42 U.S.C. 290bb-1), as amended by section 
     1002 and redesignated by subsection (a), is further amended 
     by adding at the end the following new sentence: ``Of the 
     amounts made available for a year pursuant to the previous 
     sentence to carry out this section, not more than 25 percent 
     of such amounts shall be made available for such year to 
     carry out subsection (r), other than paragraph (5) of such 
     subsection. Notwithstanding the preceding sentence, no funds 
     shall be made available to carry out subsection (r) for a 
     fiscal year unless the amount made available to carry out 
     this section for such fiscal year is more than the amount 
     made available to carry out this section for fiscal year 
     2016.''.

     SEC. 1004. CUT-GO COMPLIANCE.

       Subsection (f) of section 319D of the Public Health Service 
     Act (42 U.S.C. 247d-4) is amended by striking ``through 
     2018'' and inserting ``through 2016, $133,300,000 for fiscal 
     year 2017, and $138,300,000 for fiscal year 2018''.

       TITLE XI--VETERAN EMERGENCY MEDICAL TECHNICIAN SUPPORT ACT

     SEC. 1101. SHORT TITLE.

       This title may be cited as the ``Veteran Emergency Medical 
     Technician Support Act of 2016''.

     SEC. 1102. ASSISTING VETERANS WITH MILITARY EMERGENCY MEDICAL 
                   TRAINING TO MEET REQUIREMENTS FOR BECOMING 
                   CIVILIAN EMERGENCY MEDICAL TECHNICIANS.

       Part B of title III of the Public Health Service Act (42 
     U.S.C. 243 et seq.) is amended by inserting after section 314 
     the following:

     ``SEC. 315. ASSISTING VETERANS WITH MILITARY EMERGENCY 
                   MEDICAL TRAINING TO MEET REQUIREMENTS FOR 
                   BECOMING CIVILIAN EMERGENCY MEDICAL 
                   TECHNICIANS.

       ``(a) Program.--The Secretary shall establish a program 
     consisting of awarding demonstration grants to States to 
     streamline State requirements and procedures in order to 
     assist veterans who completed military emergency medical 
     technician training while serving in the Armed Forces of the 
     United States to meet certification, licensure, and other 
     requirements applicable to becoming an emergency medical 
     technician in the State.
       ``(b) Use of Funds.--Amounts received as a demonstration 
     grant under this section shall be used to prepare and 
     implement a plan to streamline State requirements and 
     procedures as described in subsection (a), including by--
       ``(1) determining the extent to which the requirements for 
     the education, training, and skill level of emergency medical 
     technicians in the State are equivalent to requirements for 
     the education, training, and skill level of military 
     emergency medical technicians; and
       ``(2) identifying methods, such as waivers, for military 
     emergency medical technicians to forgo or meet any such 
     equivalent State requirements.
       ``(c) Eligibility.--To be eligible for a grant under this 
     section, a State shall demonstrate that the State has a 
     shortage of emergency medical technicians.
       ``(d) Report.--The Secretary shall submit to the Congress 
     an annual report on the program under this section.
       ``(e) Funding.--No additional funds are authorized to be 
     appropriated for the purpose of carrying out this section. 
     This section shall be carried out using amounts otherwise 
     available for such purpose.''.

                   TITLE XII--JOHN THOMAS DECKER ACT

     SEC. 1201. SHORT TITLE.

       This title may be cited as the ``John Thomas Decker Act of 
     2016''.

     SEC. 1202. INFORMATION MATERIALS AND RESOURCES TO PREVENT 
                   ADDICTION RELATED TO YOUTH SPORTS INJURIES.

       (a) Technical Clarification.--Effective as if included in 
     the enactment of the Children's Health Act of 2000 (Public 
     Law 106-310), section 3405(a) of such Act (114 Stat. 1221) is 
     amended by striking ``Part E of title III'' and inserting 
     ``Part E of title III of the Public Health Service Act''.
       (b) Amendment.--Title III of the Public Health Service Act 
     is amended by inserting after part D of such title (42 U.S.C. 
     254b et seq.) the following new part E:

                     ``PART E--OPIOID USE DISORDER

     ``SEC. 341. INFORMATION MATERIALS AND RESOURCES TO PREVENT 
                   ADDICTION RELATED TO YOUTH SPORTS INJURIES.

       ``(a) Report.--The Secretary shall--
       ``(1) not later than 24 months after the date of the 
     enactment of this section, make publicly available a report 
     determining the extent to which informational materials and 
     resources described in subsection (b) are available to 
     teenagers and adolescents who play youth sports, families of 
     such teenagers and adolescents, nurses, youth sports groups, 
     and relevant health care provider groups; and
       ``(2) for purposes of educating and preventing addiction in 
     teenagers and adolescents who are injured playing youth 
     sports and are subsequently prescribed an opioid, not later 
     than 12 months after such report is made publicly available 
     and taking into consideration the findings of such report, 
     develop and, in coordination with youth sports groups, 
     disseminate informational materials and resources described 
     in subsection (b) for teenagers and adolescents who play 
     youth sports, families of such teenagers and adolescents, 
     nurses, youth sports groups, and relevant health care 
     provider groups.
       ``(b) Materials and Resources Described.--For purposes of 
     this section, the informational materials and resources 
     described in this subsection are informational materials and 
     resources with respect to youth sports injuries for which 
     opioids are potentially prescribed and

[[Page H2365]]

     subsequently potentially lead to addiction, including 
     materials and resources focused on the dangers of opioid use 
     and misuse, treatment options for such injuries that do not 
     involve the use of opioids, and how to seek treatment for 
     addiction.
       ``(c) No Additional Funds.--No additional funds are 
     authorized to be appropriated for the purpose of carrying out 
     this section. This section shall be carried out using amounts 
     otherwise available for such purpose.''.

                         TITLE XIII--LALI'S LAW

     SEC. 1301. SHORT TITLE.

       This title may be cited as ``Lali's Law''.

     SEC. 1302. OPIOID OVERDOSE REVERSAL MEDICATION ACCESS AND 
                   EDUCATION GRANT PROGRAMS.

       (a) Technical Clarification.--Effective as if included in 
     the enactment of the Children's Health Act of 2000 (Public 
     Law 106-310), section 3405(a) of such Act (114 Stat. 1221) is 
     amended by striking ``Part E of title III'' and inserting 
     ``Part E of title III of the Public Health Service Act''.
       (b) Amendment.--Title III of the Public Health Service Act 
     is amended by inserting after part D of such title (42 U.S.C. 
     254b et seq.) the following new part E:

                     ``PART E--OPIOID USE DISORDER

     ``SEC. 341. OPIOID OVERDOSE REVERSAL MEDICATION ACCESS AND 
                   EDUCATION GRANT PROGRAMS.

       ``(a) Grants to States.--The Secretary may make grants to 
     States for--
       ``(1) developing standing orders for pharmacies regarding 
     opioid overdose reversal medication;
       ``(2) encouraging pharmacies to dispense opioid overdose 
     reversal medication pursuant to a standing order;
       ``(3) implementing best practices for persons authorized to 
     prescribe medication regarding--
       ``(A) prescribing opioids for the treatment of chronic 
     pain;
       ``(B) co-prescribing opioid overdose reversal medication 
     with opioids; and
       ``(C) discussing the purpose and administration of opioid 
     overdose reversal medication with patients;
       ``(4) developing or adapting training materials and methods 
     for persons authorized to prescribe or dispense medication to 
     use in educating the public regarding--
       ``(A) when and how to administer opioid overdose reversal 
     medication; and
       ``(B) steps to be taken after administering opioid overdose 
     reversal medication; and
       ``(5) educating the public regarding--
       ``(A) the public health benefits of opioid overdose 
     reversal medication; and
       ``(B) the availability of opioid overdose reversal 
     medication without a person-specific prescription.
       ``(b) Certain Requirement.--A grant may be made under this 
     section only if the State involved has authorized standing 
     orders regarding opioid overdose reversal medication.
       ``(c) Preference in Making Grants.--In making grants under 
     this section, the Secretary shall give preference to States 
     that--
       ``(1) have not issued standing orders regarding opioid 
     overdose reversal medication;
       ``(2) authorize standing orders that permit community-based 
     organizations, substance abuse programs, or other nonprofit 
     entities to acquire, dispense, or administer opioid overdose 
     reversal medication;
       ``(3) authorize standing orders that permit police, fire, 
     or emergency medical services agencies to acquire and 
     administer opioid overdose reversal medication;
       ``(4) have a higher per capita rate of opioid overdoses 
     than other applicant States; or
       ``(5) meet any other criteria deemed appropriate by the 
     Secretary.
       ``(d) Grant Terms.--
       ``(1) Number.--A State may not receive more than one grant 
     under this section.
       ``(2) Period.--A grant under this section shall be for a 
     period of 3 years.
       ``(3) Amount.--A grant under this section may not exceed 
     $500,000.
       ``(4) Limitation.--A State may use not more than 20 percent 
     of a grant under this section for educating the public 
     pursuant to subsection (a)(5).
       ``(e) Applications.--To be eligible to receive a grant 
     under this section, a State shall submit an application to 
     the Secretary in such form and manner and containing such 
     information as the Secretary may require, including detailed 
     proposed expenditures of grant funds.
       ``(f) Reporting.--Not later than 3 months after the 
     Secretary disburses the first grant payment to any State 
     under this section and every 6 months thereafter for 3 years, 
     such State shall submit a report to the Secretary that 
     includes the following:
       ``(1) The name and ZIP Code of each pharmacy in the State 
     that dispenses opioid overdose reversal medication under a 
     standing order.
       ``(2) The total number of opioid overdose reversal 
     medication doses dispensed by each such pharmacy, specifying 
     how many were dispensed with or without a person-specific 
     prescription.
       ``(3) The number of pharmacists in the State who have 
     participated in training pursuant to subsection (a)(4).
       ``(g) Definitions.--In this section:
       ``(1) Opioid overdose reversal medication.--The term 
     `opioid overdose reversal medication' means any drug, 
     including naloxone, that--
       ``(A) blocks opioids from attaching to, but does not itself 
     activate, opioid receptors; or
       ``(B) inhibits the effects of opioids on opioid receptors.
       ``(2) Standing order.--The term `standing order' means a 
     document prepared by a person authorized to prescribe 
     medication that permits another person to acquire, dispense, 
     or administer medication without a person-specific 
     prescription.
       ``(h) Authorization of Appropriations.--
       ``(1) In general.--To carry out this section, there is 
     authorized to be appropriated $5,000,000 for the period of 
     fiscal years 2017 through 2019.
       ``(2) Administrative costs.--Not more than 3 percent of the 
     amounts made available to carry out this section may be used 
     by the Secretary for administrative expenses of carrying out 
     this section.''.

     SEC. 1303. CUT-GO COMPLIANCE.

       Subsection (f) of section 319D of the Public Health Service 
     Act (42 U.S.C. 247d-4) is amended by inserting before the 
     period at the end the following: ``(except such dollar amount 
     shall be reduced by $5,000,000 for fiscal year 2017)''.

               TITLE XIV--REDUCING UNUSED MEDICATIONS ACT

     SEC. 1401. SHORT TITLE.

       This title may be cited as the ``Reducing Unused 
     Medications Act of 2016''.

     SEC. 1402. PARTIAL FILLS OF SCHEDULE II CONTROLLED 
                   SUBSTANCES.

       (a) In General.--Section 309 of the Controlled Substances 
     Act (21 U.S.C. 829) is amended by adding at the end the 
     following:
       ``(f) Partial Fills of Schedule II Controlled Substances.--
       ``(1) Partial fills.--
       ``(A) In general.--A prescription for a controlled 
     substance in schedule II may be partially filled if--
       ``(i) it is not prohibited by State law;
       ``(ii) the prescription is written and filled in accordance 
     with the Controlled Substances Act (21 U.S.C. 801 et seq.), 
     regulations prescribed by the Attorney General, and State 
     law;
       ``(iii) the partial fill is requested by the patient or the 
     practitioner that wrote the prescription; and
       ``(iv) the total quantity dispensed in all partial fillings 
     does not exceed the total quantity prescribed.
       ``(B) Other circumstances.--A prescription for a controlled 
     substance in schedule II may be partially filled in 
     accordance with section 1306.13 of title 21, Code of Federal 
     Regulations (as in effect on the date of enactment of the 
     Reducing Unused Medications Act).
       ``(2) Remaining portions.--
       ``(A) In general.--Except as provided in subparagraph (B), 
     remaining portions of a partially filled prescription for a 
     controlled substance in schedule II--
       ``(i) may be filled; and
       ``(ii) shall be filled not later than 30 days after the 
     date on which the prescription is written.
       ``(B) Emergency situations.--In emergency situations, as 
     described in subsection (a), the remaining portions of a 
     partially filled prescription for a controlled substance in 
     schedule II--
       ``(i) may be filled; and
       ``(ii) shall be filled not later than 72 hours after the 
     prescription is issued.''.
       (b) Rule of Construction.--Nothing in this section shall be 
     construed to affect the authority of the Attorney General to 
     allow a prescription for a controlled substance in schedule 
     III, IV, or V of section 202(c) of the Controlled Substances 
     Act (21 U.S.C. 812(c)) to be partially filled.

               TITLE XV--OPIOID REVIEW MODERNIZATION ACT

     SEC. 1501. SHORT TITLE.

       This title may be cited as the ``Opioid Review 
     Modernization Act of 2016''.

     SEC. 1502. FDA OPIOID ACTION PLAN.

       Chapter V of the Federal Food, Drug, and Cosmetic Act is 
     amended by inserting after section 569 of such Act (21 U.S.C. 
     350bbb-8) the following:

     ``SEC. 569-1. OPIOID ACTION PLAN.

       ``(a) New Drug Application.--
       ``(1) In general.--Subject to paragraph (2), prior to the 
     approval pursuant to an application under section 505(b) of a 
     new drug that is an opioid and does not have abuse-deterrent 
     properties, the Secretary shall refer the application to an 
     advisory committee of the Food and Drug Administration to 
     seek recommendations from such advisory committee.
       ``(2) Public health exemption.--A referral to an advisory 
     committee under paragraph (1) is not required with respect to 
     a new drug if the Secretary--
       ``(A) finds that such a referral is not in the interest of 
     protecting and promoting public health;
       ``(B) finds that such a referral is not necessary based on 
     a review of the relevant scientific information; and
       ``(C) submits a notice containing the rationale for such 
     findings to the Committee on Health, Education, Labor, and 
     Pensions of the Senate and the Committee on Energy and 
     Commerce of the House of Representatives.
       ``(b) Pediatric Opioid Labeling.--The Secretary shall 
     convene the Pediatric Advisory Committee of the Food and Drug 
     Administration to seek recommendations from such Committee 
     regarding a framework for the inclusion of information in the 
     labeling of drugs that are opioids relating to the use of 
     such drugs in pediatric populations before the Secretary 
     approves any labeling or change to labeling for any drug that 
     is an opioid intended for use in a pediatric population.
       ``(c) Sunset.--The requirements of subsections (a) and (b) 
     shall cease to be effective on October 1, 2022.''.

     SEC. 1503. PRESCRIBER EDUCATION.

       Not later than 1 year after the date of the enactment of 
     this Act, the Secretary of Health and Human Services, acting 
     through the Commissioner of Food and Drugs, as part of the 
     Food and Drug Administration's evaluation of the Extended-
     Release/Long-Acting Opioid Analgesics Risk Evaluation and 
     Mitigation Strategy, and in consultation with relevant 
     stakeholders, shall develop recommendations regarding 
     education programs for prescribers of opioids pursuant to 
     section 505-1 of the Federal Food, Drug,

[[Page H2366]]

     and Cosmetic Act (21 U.S.C. 355-1), including recommendations 
     on--
       (1) which prescribers should participate in such programs; 
     and
       (2) how often participation in such programs is necessary.

     SEC. 1504. GUIDANCE ON EVALUATING THE ABUSE DETERRENCE OF 
                   GENERIC SOLID ORAL OPIOID DRUG PRODUCTS.

       Not later than 2 years after the end of the period for 
     public comment on the draft guidance entitled ``General 
     Principals for Evaluating the Abuse Deterrence of Generic 
     Solid Oral Opioid Drug Products'' issued by the Center for 
     Drug Evaluation and Research of the Food and Drug 
     Administration in March 2016, the Commissioner of Food and 
     Drugs shall publish in the Federal Register a final version 
     of such guidance.

        TITLE XVI--EXAMINING OPIOID TREATMENT INFRASTRUCTURE ACT

     SEC. 1601. SHORT TITLE.

       This title may be cited as the ``Examining Opioid Treatment 
     Infrastructure Act of 2016''.

     SEC. 1602. STUDY ON TREATMENT INFRASTRUCTURE.

       Not later than 24 months after the date of enactment of 
     this Act, the Comptroller General of the United States shall 
     initiate an evaluation, and submit to Congress a report, of 
     the inpatient and outpatient treatment capacity, 
     availability, and needs of the United States, which shall 
     include, to the extent data are available--
       (1) the capacity of acute residential or inpatient 
     detoxification programs;
       (2) the capacity of inpatient clinical stabilization 
     programs, transitional residential support services, and 
     residential rehabilitation programs;
       (3) the capacity of demographic specific residential or 
     inpatient treatment programs, such as those designed for 
     pregnant women or adolescents;
       (4) geographical differences of the availability of 
     residential and outpatient treatment and recovery options for 
     substance use disorders across the continuum of care;
       (5) the availability of residential and outpatient 
     treatment programs that offer treatment options based on 
     reliable scientific evidence of efficacy for the treatment of 
     substance use disorders, including the use of Food and Drug 
     Administration-approved medicines and evidence-based 
     nonpharmacological therapies;
       (6) the number of patients in residential and specialty 
     outpatient treatment services for substance use disorders;
       (7) an assessment of the need for residential and 
     outpatient treatment for substance use disorders across the 
     continuum of care;
       (8) the availability of residential and outpatient 
     treatment programs to American Indians and Alaska Natives 
     through an Indian health program (as defined by section 4 of 
     the Indian Health Care Improvement Act (25 U.S.C. 1603)); and
       (9) the barriers (including technological barriers) at the 
     Federal, State, and local levels to real-time reporting of 
     de-identified information on drug overdoses and ways to 
     overcome such barriers.

 TITLE XVII--OPIOID USE DISORDER TREATMENT EXPANSION AND MODERNIZATION 
                                  ACT

     SEC. 1701. SHORT TITLE.

       This title may be cited as the ``Opioid Use Disorder 
     Treatment Expansion and Modernization Act''.

     SEC. 1702. FINDING.

       The Congress finds that opioid use disorder has become a 
     public health epidemic that must be addressed by increasing 
     awareness and access to all treatment options for opioid use 
     disorder, overdose reversal, and relapse prevention.

     SEC. 1703. OPIOID USE DISORDER TREATMENT MODERNIZATION.

       (a) In General.--Section 303(g)(2) of the Controlled 
     Substances Act (21 U.S.C. 823(g)(2)) is amended--
       (1) in subparagraph (B), by striking clauses (i), (ii), and 
     (iii) and inserting the following:
       ``(i) The practitioner is a qualifying practitioner (as 
     defined in subparagraph (G)).
       ``(ii) With respect to patients to whom the practitioner 
     will provide such drugs or combinations of drugs, the 
     practitioner has the capacity to provide directly, by 
     referral, or in such other manner as determined by the 
     Secretary--
       ``(I) all schedule III, IV, and V drugs, as well as 
     unscheduled medications approved by the Food and Drug 
     Administration, for the treatment of opioid use disorder, 
     including such drugs and medications for maintenance, 
     detoxification, overdose reversal, and relapse prevention, as 
     available; and
       ``(II) appropriate counseling and other appropriate 
     ancillary services.
       ``(iii)(I) The total number of such patients of the 
     practitioner at any one time will not exceed the applicable 
     number. Except as provided in subclause (II), the applicable 
     number is 30.
       ``(II) The applicable number is 100 if, not sooner than 1 
     year after the date on which the practitioner submitted the 
     initial notification, the practitioner submits a second 
     notification to the Secretary of the need and intent of the 
     practitioner to treat up to 100 patients.
       ``(III) The Secretary may by regulation change such total 
     number.
       ``(IV) The Secretary may exclude from the applicable number 
     patients to whom such drugs or combinations of drugs are 
     directly administered by the qualifying practitioner in the 
     office setting.
       ``(iv) If the Secretary by regulation increases the total 
     number of patients which a qualifying practitioner is 
     permitted to treat pursuant to clause (iii)(II), the 
     Secretary shall require such a practitioner to obtain a 
     written agreement from each patient, including the patient's 
     signature, that the patient--
       ``(I) will receive an initial assessment and treatment plan 
     and periodic assessments and treatment plans thereafter;
       ``(II) will be subject to medication adherence and 
     substance use monitoring;
       ``(III) understands available treatment options, including 
     all drugs approved by the Food and Drug Administration for 
     the treatment of opioid use disorder, including their 
     potential risks and benefits; and
       ``(IV) understands that receiving regular counseling 
     services is critical to recovery.
       ``(v) The practitioner will comply with the reporting 
     requirements of subparagraph (D)(i)(IV).'';
       (2) in subparagraph (D)--
       (A) in clause (i), by adding at the end the following:
       ``(IV) The practitioner reports to the Secretary, at such 
     times and in such manner as specified by the Secretary, such 
     information and assurances as the Secretary determines 
     necessary to assess whether the practitioner continues to 
     meet the requirements for a waiver under this paragraph.'';
       (B) in clause (ii), by striking ``Upon receiving a 
     notification under subparagraph (B)'' and inserting ``Upon 
     receiving a determination from the Secretary under clause 
     (iii) finding that a practitioner meets all requirements for 
     a waiver under subparagraph (B)''; and
       (C) in clause (iii)--
       (i) by inserting ``and shall forward such determination to 
     the Attorney General'' before the period at the end of the 
     first sentence; and
       (ii) by striking ``physician'' and inserting 
     ``practitioner'';
       (3) in subparagraph (G)--
       (A) by amending clause (ii)(IV) to read as follows:
       ``(IV) The physician has, with respect to the treatment and 
     management of opiate-dependent patients, completed not less 
     than 8 hours of training (through classroom situations, 
     seminars at professional society meetings, electronic 
     communications, or otherwise) that is provided by the 
     American Society of Addiction Medicine, the American Academy 
     of Addiction Psychiatry, the American Medical Association, 
     the American Osteopathic Association, the American 
     Psychiatric Association, or any other organization that the 
     Secretary determines is appropriate for purposes of this 
     subclause. Such training shall address--
       ``(aa) opioid maintenance and detoxification;
       ``(bb) appropriate clinical use of all drugs approved by 
     the Food and Drug Administration for the treatment of opioid 
     use disorder;
       ``(cc) initial and periodic patient assessments (including 
     substance use monitoring);
       ``(dd) individualized treatment planning; overdose 
     reversal; relapse prevention;
       ``(ee) counseling and recovery support services;
       ``(ff) staffing roles and considerations;
       ``(gg) diversion control; and
       ``(hh) other best practices, as identified by the 
     Secretary.''; and
       (B) by adding at the end the following:
       ``(iii) The term `qualifying practitioner' means--
       ``(I) a qualifying physician, as defined in clause (ii); or
       ``(II) during the period beginning on the date of the 
     enactment of the Opioid Use Disorder Treatment Expansion and 
     Modernization Act and ending on the date that is 3 years 
     after such date of enactment, a qualifying other 
     practitioner, as defined in clause (iv).
       ``(iv) The term `qualifying other practitioner' means a 
     nurse practitioner or physician assistant who satisfies each 
     of the following:
       ``(I) The nurse practitioner or physician assistant is 
     licensed under State law to prescribe schedule III, IV, or V 
     medications for the treatment of pain.
       ``(II) The nurse practitioner or physician assistant 
     satisfies one or more of the following:
       ``(aa) Has completed not fewer than 24 hours of initial 
     training addressing each of the topics listed in clause 
     (ii)(IV) (through classroom situations, seminars at 
     professional society meetings, electronic communications, or 
     otherwise) provided by the American Society of Addiction 
     Medicine, the American Academy of Addiction Psychiatry, the 
     American Medical Association, the American Osteopathic 
     Association, the American Nurses Credentialing Center, the 
     American Psychiatric Association, the American Association of 
     Nurse Practitioners, the American Academy of Physician 
     Assistants, or any other organization that the Secretary 
     determines is appropriate for purposes of this subclause.
       ``(bb) Has such other training or experience as the 
     Secretary determines will demonstrate the ability of the 
     nurse practitioner or physician assistant to treat and manage 
     opiate-dependent patients.
       ``(III) The nurse practitioner or physician assistant is 
     supervised by or works in collaboration with a qualifying 
     physician, if the nurse practitioner or physician assistant 
     is required by State law to prescribe medications for the 
     treatment of opioid use disorder in collaboration with or 
     under the supervision of a physician

     .The Secretary may review and update the requirements for 
     being a qualifying other practitioner under this clause.''; 
     and
       (4) in subparagraph (H)--
       (A) in clause (i), by inserting after subclause (II) the 
     following:
       ``(III) Such other elements of the requirements under this 
     paragraph as the Secretary determines necessary for purposes 
     of implementing such requirements.''; and
       (B) by amending clause (ii) to read as follows:
       ``(ii) Not later than 1 year after the date of enactment of 
     the Opioid Use Disorder Treatment Expansion and Modernization 
     Act, the Secretary shall update the treatment improvement

[[Page H2367]]

     protocol containing best practice guidelines for the 
     treatment of opioid-dependent patients in office-based 
     settings. The Secretary shall update such protocol in 
     consultation with experts in opioid use disorder research and 
     treatment.''.
       (b) Recommendation of Revocation or Suspension of 
     Registration in Case of Substantial Noncompliance.--The 
     Secretary of Health and Human Services may recommend to the 
     Attorney General that the registration of a practitioner be 
     revoked or suspended if the Secretary determines, according 
     to such criteria as the Secretary establishes by regulation, 
     that a practitioner who is registered under section 303(g)(2) 
     of the Controlled Substances Act (21 U.S.C. 823(g)(2)) is not 
     in substantial compliance with the requirements of such 
     section, as amended by this Act.
       (c) Opioid Defined.--Section 102(18) of the Controlled 
     Substances Act (21 U.S.C. 802(18)) is amended by inserting 
     ``or `opioid' '' after ``The term `opiate' ''.
       (d) Reports to Congress.--
       (1) In general.--Not later than 2 years after the date of 
     enactment of this Act and not less than over every 5 years 
     thereafter, the Secretary of Health and Human Services, in 
     consultation with the Drug Enforcement Administration and 
     experts in opioid use disorder research and treatment, 
     shall--
       (A) perform a thorough review of the provision of opioid 
     use disorder treatment services in the United States, 
     including services provided in opioid treatment programs and 
     other specialty and nonspecialty settings; and
       (B) submit a report to the Congress on the findings and 
     conclusions of such review.
       (2) Contents.--Each report under paragraph (1) shall 
     include an assessment of--
       (A) compliance with the requirements of section 303(g)(2) 
     of the Controlled Substances Act (21 U.S.C. 823(g)(2)), as 
     amended by this Act;
       (B) the measures taken by the Secretary of Health and Human 
     Services to ensure such compliance;
       (C) whether there is further need to increase or decrease 
     the number of patients a waivered practitioner is permitted 
     to treat, as provided for by the amendment made by subsection 
     (a)(1);
       (D) the extent to which, and proportions with which, the 
     full range of Food and Drug Administration-approved 
     treatments for opioid use disorder are used in routine health 
     care settings and specialty substance use disorder treatment 
     settings;
       (E) access to, and use of, counseling and recovery support 
     services, including the percentage of patients receiving such 
     services;
       (F) changes in State or local policies and legislation 
     relating to opioid use disorder treatment;
       (G) the use of prescription drug monitoring programs by 
     practitioners who are permitted to dispense narcotic drugs to 
     individuals pursuant to a waiver under section 303(g)(2) of 
     the Controlled Substances Act (21 U.S.C. 823(g)(2));
       (H) the findings resulting from inspections by the Drug 
     Enforcement Administration of practitioners described in 
     subparagraph (G); and
       (I) the effectiveness of cross-agency collaboration between 
     Department of Health and Human Services and the Drug 
     Enforcement Administration for expanding effective opioid use 
     disorder treatment.

     SEC. 1704. SENSE OF CONGRESS.

       It is the Sense of Congress that, with respect to the total 
     number of patients that a qualifying physician (as defined in 
     subparagraph (G)(iii) of section 303(g)(2) of the Controlled 
     Substances Act (21 U.S.C. 823(g)(2)) can treat at any one 
     time pursuant to such section, the Secretary of Health and 
     Human Services should consider raising such total number to 
     250 patients following a third notification to the Secretary 
     of the need and intent of the physician to treat up to 250 
     patients that is submitted to the Secretary not sooner than 1 
     year after the date on which the physician submitted to the 
     Secretary a second notification to treat up to 100 patients.

     SEC. 1705. PARTIAL FILLS OF SCHEDULE II CONTROLLED 
                   SUBSTANCES.

       (a) In General.--Section 309 of the Controlled Substances 
     Act (21 U.S.C. 829) is amended by adding at the end the 
     following:
       ``(f) Partial Fills of Schedule II Controlled Substances.--
       ``(1) Partial fills.--
       ``(A) In general.--A prescription for a controlled 
     substance in schedule II may be partially filled if--
       ``(i) it is not prohibited by State law;
       ``(ii) the prescription is written and filled in accordance 
     with the Controlled Substances Act (21 U.S.C. 801 et seq.), 
     regulations prescribed by the Attorney General, and State 
     law;
       ``(iii) the partial fill is requested by the patient or the 
     practitioner that wrote the prescription; and
       ``(iv) the total quantity dispensed in all partial fillings 
     does not exceed the total quantity prescribed.
       ``(B) Other circumstances.--A prescription for a controlled 
     substance in schedule II may be partially filled in 
     accordance with section 1306.13 of title 21, Code of Federal 
     Regulations (as in effect on the date of enactment of the 
     Reducing Unused Medications Act of 2016).
       ``(2) Remaining portions.--
       ``(A) In general.--Except as provided in subparagraph (B), 
     remaining portions of a partially filled prescription for a 
     controlled substance in schedule II--
       ``(i) may be filled; and
       ``(ii) shall be filled not later than 30 days after the 
     date on which the prescription is written.
       ``(B) Emergency situations.--In emergency situations, as 
     described in subsection (a), the remaining portions of a 
     partially filled prescription for a controlled substance in 
     schedule II--
       ``(i) may be filled; and
       ``(ii) shall be filled not later than 72 hours after the 
     prescription is issued.''.
       (b) Rule of Construction.--Nothing in this section shall be 
     construed to affect the authority of the Attorney General to 
     allow a prescription for a controlled substance in schedule 
     III, IV, or V of section 202(c) of the Controlled Substances 
     Act (21 U.S.C. 812(c)) to be partially filled.

 TITLE XVIII--NATIONAL ALL SCHEDULES PRESCRIPTION ELECTRONIC REPORTING 
                          REAUTHORIZATION ACT

     SEC. 1801. SHORT TITLE.

       This title may be cited as the ``National All Schedules 
     Prescription Electronic Reporting Reauthorization Act of 
     2015''.

     SEC. 1802. AMENDMENT TO PURPOSE.

       Paragraph (1) of section 2 of the National All Schedules 
     Prescription Electronic Reporting Act of 2005 (Public Law 
     109-60) is amended to read as follows:
       ``(1) foster the establishment of State-administered 
     controlled substance monitoring systems in order to ensure 
     that--
       ``(A) health care providers have access to the accurate, 
     timely prescription history information that they may use as 
     a tool for the early identification of patients at risk for 
     addiction in order to initiate appropriate medical 
     interventions and avert the tragic personal, family, and 
     community consequences of untreated addiction; and
       ``(B) appropriate law enforcement, regulatory, and State 
     professional licensing authorities have access to 
     prescription history information for the purposes of 
     investigating drug diversion and prescribing and dispensing 
     practices of errant prescribers or pharmacists; and''.

     SEC. 1803. AMENDMENTS TO CONTROLLED SUBSTANCE MONITORING 
                   PROGRAM.

       Section 399O of the Public Health Service Act (42 U.S.C. 
     280g-3) is amended--
       (1) in subsection (a)--
       (A) in paragraph (1)--
       (i) in subparagraph (A), by striking ``or'';
       (ii) in subparagraph (B), by striking the period at the end 
     and inserting ``; or''; and
       (iii) by adding at the end the following:
       ``(C) to maintain and operate an existing State-controlled 
     substance monitoring program.''; and
       (B) in paragraph (3), by inserting ``by the Secretary'' 
     after ``Grants awarded'';
       (2) by amending subsection (b) to read as follows:
       ``(b) Minimum Requirements.--The Secretary shall maintain 
     and, as appropriate, supplement or revise (after publishing 
     proposed additions and revisions in the Federal Register and 
     receiving public comments thereon) minimum requirements for 
     criteria to be used by States for purposes of clauses (ii), 
     (v), (vi), and (vii) of subsection (c)(1)(A).'';
       (3) in subsection (c)--
       (A) in paragraph (1)(B)--
       (i) in the matter preceding clause (i), by striking 
     ``(a)(1)(B)'' and inserting ``(a)(1)(B) or (a)(1)(C)'';
       (ii) in clause (i), by striking ``program to be improved'' 
     and inserting ``program to be improved or maintained'';
       (iii) by redesignating clauses (iii) and (iv) as clauses 
     (iv) and (v), respectively;
       (iv) by inserting after clause (ii) the following:
       ``(iii) a plan to apply the latest advances in health 
     information technology in order to incorporate prescription 
     drug monitoring program data directly into the workflow of 
     prescribers and dispensers to ensure timely access to 
     patients' controlled prescription drug history;'';
       (v) in clause (iv), as redesignated, by inserting before 
     the semicolon at the end ``and at least one health 
     information technology system such as an electronic health 
     records system, a health information exchange, or an e-
     prescribing system''; and
       (vi) in clause (v), as redesignated, by striking ``public 
     health'' and inserting ``public health or public safety'';
       (B) in paragraph (3)--
       (i) by striking ``If a State that submits'' and inserting 
     the following:
       ``(A) In general.--If a State that submits'';
       (ii) by striking the period at the end and inserting ``and 
     include timelines for full implementation of such 
     interoperability. The State shall also describe the manner in 
     which it will achieve interoperability between its monitoring 
     program and health information technology systems, as 
     allowable under State law, and include timelines for 
     implementation of such interoperability.''; and
       (iii) by adding at the end the following:
       ``(B) Monitoring of efforts.--The Secretary shall monitor 
     State efforts to achieve interoperability, as described in 
     subparagraph (A).''; and
       (C) in paragraph (5)--
       (i) by striking ``implement or improve'' and inserting 
     ``establish, improve, or maintain''; and
       (ii) by adding at the end the following: ``The Secretary 
     shall redistribute any funds that are so returned among the 
     remaining grantees under this section in accordance with the 
     formula described in subsection (a)(2)(B).'';
       (4) in subsection (d)--
       (A) in the matter preceding paragraph (1)--
       (i) by striking ``In implementing or improving'' and all 
     that follows through ``(a)(1)(B)'' and inserting ``In 
     establishing, improving, or maintaining a controlled 
     substance monitoring program under this section, a State 
     shall comply, or with respect to a State that applies for a 
     grant under subparagraph (B) or (C) of subsection (a)(1)''; 
     and
       (ii) by striking ``public health'' and inserting ``public 
     health or public safety''; and
       (B) by adding at the end the following:
       ``(5) The State shall report to the Secretary on--
       ``(A) as appropriate, interoperability with the controlled 
     substance monitoring programs of Federal departments and 
     agencies;
       ``(B) as appropriate, interoperability with health 
     information technology systems such as

[[Page H2368]]

     electronic health records systems, health information 
     exchanges, and e-prescribing systems; and
       ``(C) whether or not the State provides automatic, real-
     time or daily information about a patient when a practitioner 
     (or the designee of a practitioner, where permitted) requests 
     information about such patient.'';
       (5) in subsections (e), (f)(1), and (g), by striking 
     ``implementing or improving'' each place it appears and 
     inserting ``establishing, improving, or maintaining'';
       (6) in subsection (f)--
       (A) in paragraph (1)--
       (i) in subparagraph (B), by striking ``misuse of a schedule 
     II, III, or IV substance'' and inserting ``misuse of a 
     controlled substance included in schedule II, III, or IV of 
     section 202(c) of the Controlled Substance Act''; and
       (ii) in subparagraph (D), by inserting ``a State substance 
     abuse agency,'' after ``a State health department,''; and
       (B) by adding at the end the following:
       ``(3) Evaluation and reporting.--Subject to subsection (g), 
     a State receiving a grant under subsection (a) shall provide 
     the Secretary with aggregate data and other information 
     determined by the Secretary to be necessary to enable the 
     Secretary--
       ``(A) to evaluate the success of the State's program in 
     achieving its purposes; or
       ``(B) to prepare and submit the report to Congress required 
     by subsection (l)(2).
       ``(4) Research by other entities.--A department, program, 
     or administration receiving nonidentifiable information under 
     paragraph (1)(D) may make such information available to other 
     entities for research purposes.'';
       (7) by redesignating subsections (h) through (n) as 
     subsections (j) through (p), respectively;
       (8) in subsections (c)(1)(A)(iv) and (d)(4), by striking 
     ``subsection (h)'' each place it appears and inserting 
     ``subsection (j)'';
       (9) by inserting after subsection (g) the following:
       ``(h) Education and Access to the Monitoring System.--A 
     State receiving a grant under subsection (a) shall take steps 
     to--
       ``(1) facilitate prescriber and dispenser use of the 
     State's controlled substance monitoring system;
       ``(2) educate prescribers and dispensers on the benefits of 
     the system both to them and society; and
       ``(3) facilitate linkage to the State substance abuse 
     agency and substance abuse disorder services.
       ``(i) Consultation With Attorney General.--In carrying out 
     this section, the Secretary shall consult with the Attorney 
     General of the United States and other relevant Federal 
     officials to--
       ``(1) ensure maximum coordination of controlled substance 
     monitoring programs and related activities; and
       ``(2) minimize duplicative efforts and funding.'';
       (10) in subsection (l)(2)(A), as redesignated by paragraph 
     (7)--
       (A) in clause (ii), by inserting ``; established or 
     strengthened initiatives to ensure linkages to substance use 
     disorder services;'' before ``or affected patient access''; 
     and
       (B) in clause (iii), by inserting ``and between controlled 
     substance monitoring programs and health information 
     technology systems'' before ``, including an assessment'';
       (11) by striking subsection (m) (relating to preference), 
     as redesignated by paragraph (7);
       (12) by redesignating subsections (n) through (p), as 
     redesignated by paragraph (7), as subsections (m) through 
     (o), respectively;
       (13) in subsection (m)(1), as redesignated by paragraph 
     (12), by striking ``establishment, implementation, or 
     improvement'' and inserting ``establishment, improvement, or 
     maintenance'';
       (14) in subsection (n), as redesignated by paragraph (12)--
       (A) in paragraph (5)--
       (i) by striking ``means the ability'' and inserting the 
     following: ``means--
       ``(A) the ability'';
       (ii) by striking the period at the end and inserting ``; 
     or''; and
       (iii) by adding at the end the following:
       ``(B) sharing of State controlled substance monitoring 
     program information with a health information technology 
     system such as an electronic health records system, a health 
     information exchange, or an e-prescribing system.'';
       (B) in paragraph (7), by striking ``pharmacy'' and 
     inserting ``pharmacist''; and
       (C) in paragraph (8), by striking ``and the District of 
     Columbia'' and inserting ``, the District of Columbia, and 
     any commonwealth or territory of the United States''; and
       (15) by amending subsection (o), as redesignated by 
     paragraph (12), to read as follows:
       ``(o) Authorization of Appropriations.--To carry out this 
     section, there is authorized to be appropriated $10,000,000 
     for each of fiscal years from 2016 through 2020.''.

  The SPEAKER pro tempore. The bill shall be debatable for 1 hour, 
equally divided among and controlled by the chair and ranking minority 
member of the Committee on Energy and Commerce and the chair and 
ranking minority member of the Committee on the Judiciary.
  The gentlewoman from Indiana (Mrs. Brooks), the gentleman from New 
Jersey (Mr. Pallone), the gentleman from Virginia (Mr. Goodlatte), and 
the gentleman from Michigan (Mr. Conyers) each will control 15 minutes.
  The Chair recognizes the gentlewoman from Indiana.

                              {time}  1045


                             General Leave

  Mrs. BROOKS of Indiana. Mr. Speaker, I ask unanimous consent that all 
Members may have 5 legislative days in which to revise and extend their 
remarks and to insert extraneous material on S. 524.
  The SPEAKER pro tempore. Is there objection to the request of the 
gentlewoman from Indiana?
  There was no objection.
  Mrs. BROOKS of Indiana. Mr. Speaker, I yield myself such time as I 
may consume.
  Mr. Speaker, this week in Congress, we passed 18 bills to address the 
heroin and opioid crisis that is impacting every community in this 
country.
  I am thankful that my bill, H.R. 4641, which I worked on with 
Representative Kennedy of Massachusetts, ensures that healthcare 
professionals have access to up-to-date guidelines and best practices 
for treating patients with acute and chronic pain.
  Many of these proposals we considered this week enjoyed nearly 
unanimous support, and I can't express to you how refreshing it was to 
work with all of my colleagues on meaningful solutions to this public 
health crisis.
  As we learned from the multitude of Members this week that shared 
their stories on the House floor, we are facing a public health crisis 
that crosses every socioeconomic, every geographic, generational, and 
ethnic boundary. It is a rural, urban, and suburban problem. It reaches 
into our schools, our places of work, and our hospitals. It is tearing 
apart and devastating families and people's lives.
  However, in the midst of this crisis, as with many past crises faced 
by our Nation, we, as Members of Congress, have set aside our political 
differences and have crafted a package of thoughtful reforms that will 
support our communities ravaged by this scourge.
  I am proud of the work done by the Energy and Commerce Committee and 
the strong, bipartisan leadership by Chairmen Upton and Pitts and 
Ranking Members Pallone and Green. We cannot overlook the hard work and 
countless hours spent by both the majority and the minority committee 
staff on this effort, and I want to thank them for their hard work.
  Members of the Energy and Commerce Committee have pursued answers to 
this epidemic through roundtables and meetings with individuals and 
families on the front lines of this crisis--health workers, first 
responders, and community leaders seeking to guide their communities 
through this crisis.
  We, as Members, have visited neonatal intensive care units in 
hospitals to see firsthand the devastating effects of infants born 
addicted to opioids and who must already fight for survival through 
their withdrawal in their very first days of life.
  We have met with juvenile court judges and social workers whose 
caseloads have doubled over the past few years as more and more 
children are being removed from their parents' care because their 
parents are more concerned about where to find their next high than the 
welfare of their child and it is no longer safe for them to remain in 
their homes.
  It is important to note that it is National Police Week this week. 
And it is our first responders, whom so many of us have talked to, 
those we have heard from in Indiana, who keep naloxone in their police 
cruisers because they are seeing this unprecedented increase in drug 
overdoses, and they are saving lives each and every day.
  In a minute, my colleague from the Judiciary Committee will highlight 
all of the great work that their committee has also done to fight this 
scourge, but I would like to take a moment to highlight the bills 
rolled into this legislation that my colleagues from the Energy and 
Commerce Committee have painstakingly crafted.
  The Opioid Review Modernization Act, led by Representatives Carolyn 
B. Maloney of New York and Lance, would require the FDA to work closely 
with expert advisory committees before making critical opioid approval 
and labeling decisions, develop recommendations regarding prescriber 
education programs that address extended-release and long-acting 
opioids, and encourage the development and approval of generic opioids 
with abuse-deterrent properties.

[[Page H2369]]

  Representative Sarbanes led the Co-Prescribing to Reduce Overdoses 
Act, which would establish a grant program for co-prescribing of opioid 
reversal drugs for patients who are at a high risk of overdose.
  Representative Evan Jenkins and Representative Bustos crafted the 
Nurturing and Supporting Healthy Babies Act, which will expand our 
knowledge of care and treatment for babies with neonatal abstinence 
syndrome and fixes an unintended consequence with the Medicaid drug 
rebate program that discourages drug manufacturers from producing 
opioids that are harder to abuse.
  Representative Ben Ray Lujan of New Mexico led efforts to establish a 
pilot program that will provide grants to State substance abuse 
agencies to promote innovative service delivery models for pregnant 
women who have a substance use disorder, such as opioid addiction.
  Representative Kinzinger's Veteran Emergency Medical Technician 
Support Act will improve the quality of care within our communities by 
providing grants to States with emergency medical technician shortages 
so as to help streamline State requirements for our veterans to enter 
the EMT workforce without there being an unnecessary duplication of 
their training.
  Representatives Meehan, Kind, and Veasey led the legislation 
directing the CDC to study what information and resources are available 
to youth athletes and their families regarding the dangers of opioid 
use.
  Lali's Law, authored by Representative Dold and Representative 
Katherine Clark of Massachusetts, would create a competitive grant 
program to help States increase access to the overdose reversal 
medications that save lives.
  The Reducing Unused Medications Act, led again by Representatives 
Clark of Massachusetts and Stivers, clarifies when Schedule II 
controlled substances, including opioid pain medications, can be 
partially filled.
  Representatives Foster and Pallone spearheaded the Examining Opioid 
Treatment Infrastructure Act, which requires the GAO to collect the 
data necessary to assess the opioid infrastructure in our country, 
looking at the numbers of hospital beds and treatment facilities.
  Finally, my Hoosier colleague, Representative Bucshon, along with 
Representative Tonko, championed a bill that will expand existing 
opioid treatment capacity substantially by providers, all while 
ensuring that the care that individuals receive is high-quality and 
minimizes the risk of diversion.
  Each approach that I have just set out has been a reflection of much 
effort put into crafting this bipartisan, thoughtful, and comprehensive 
package to give each of our communities, families, and individuals with 
addictions the support they need.
  Mr. Speaker, I reserve the balance of my time.
  Mr. PALLONE. Mr. Speaker, I yield 2 minutes to the gentleman from New 
York (Mr. Engel).
  Mr. ENGEL. Mr. Speaker, I thank the gentleman for yielding to me.
  Mr. Speaker, my heart goes out to the thousands of American families 
affected by the opioid epidemic. I am pleased the House is working in a 
bipartisan manner to address this crisis. However, we could be doing 
more.
  The prescription opioid death rate has more than quadrupled since the 
late 1990s. In 2014, prescription opioids played a role in more than 
28,000 overdose deaths.
  We must equip our communities with the resources needed to reverse 
these trends. Yes, authorizing new grant programs, reports, and studies 
is an important step, but without new funding, communities won't be 
able to fully implement these initiatives.
  On Wednesday, the majority blocked a Democratic substitute opioids 
package which would have provided $600 million--paid for, I might add--
to fund the initiatives we have considered this week. I understand the 
need to get our fiscal house in order, but I don't understand the 
impulse to do so on the backs of millions of Americans grappling with 
opioid abuse.
  These bills are great, and I wholeheartedly support them, but we need 
to put our money where our mouth is. This epidemic does not 
discriminate. It has touched every corner of our Nation, from my 
hometown of New York City to the shores of the Pacific.
  So many Americans have already felt its impact. We need to do 
everything we can to keep it from impacting more of our families, our 
friends, and our constituents.

  We are on the right path, but, again, without money, this becomes 
irrelevant. We need to make sure that we have adequate funding so what 
we all want to do on both sides of the aisle can become a reality.
  Mrs. BROOKS of Indiana. Mr. Speaker, I yield 2 minutes to the 
gentleman from Michigan (Mr. Benishek).
  Mr. BENISHEK. Mr. Speaker, it is past time to give our healthcare 
providers the tools they need to confront the growing epidemic of 
opioid abuse in our country. This is an emergency.
  As a doctor who has treated patients in northern Michigan for over 30 
years, both in private practice and in the VA system, I know how urgent 
the need for immediate action is.
  The amendment to the Comprehensive Addiction and Recovery Act that we 
are considering today will be a giant step forward in how we provide 
treatment and care for those suffering from opioid addiction.
  The bill will also improve the quality of care available to our 
Nation's veterans. The rate of abuse for legal prescription drugs is 
significantly higher among our veteran population than it is in the 
general population, and this problem is only continuing to grow.
  We have an opportunity today to take a first step in fixing a major 
national problem and pass meaningful legislation that will help save 
the lives of thousands and thousands of Americans.
  Mr. Speaker, I urge my colleagues to support this legislation and 
continue working together on bipartisan solutions for our Nation's 
growing epidemic of substance abuse.
  Mr. PALLONE. Mr. Speaker, I yield 2 minutes to the gentleman from New 
York (Mr. Tonko).
  Mr. TONKO. Mr. Speaker, this week, we have seen a number of well-
intentioned bills come to the floor with good ideas on how we can 
address the Nation's opioid epidemic that is sweeping our entire 
country.
  I was proud to lead one of those efforts with my good friend 
Representative Bucshon with a bill that endeavors to lift the cap on 
the number of patients a provider may treat with buprenorphine to 250, 
while expanding prescribing privileges to nurse practitioners and 
physician assistants.
  This is a good bill, and it would make a real, immediate difference 
for individuals facing months-long waiting lists for effective 
treatment, like the gentleman that I met last week when touring an 
addiction clinic in my district. He had struggled with addiction for 
decades and, after making the decision to try to get clean, was faced 
with a closed door and a 7-month waiting list due to outdated Federal 
rules that our bill would have fixed.
  Unfortunately, when this bill came to the floor, we were told the cap 
language had to be temporarily replaced with placeholder sense-of-
Congress language until we go to conference because our bill was going 
to cost too much.
  Now, when we talk about the cost of this bill, what we are really 
talking about is the fact that more people will have access to 
effective treatment and more lives--more lives--will be saved. It is an 
unfortunate truth that, in the distorted budgetary terms of Washington, 
dead people cost less than the living.
  So we can talk all we want and we can pass all the bills we want, but 
unless we put our money where our mouth is, we will simply be peddling 
false hope. We will be condemning more of our brothers and sisters to 
the death spiral of addiction when we could have done something to 
help.
  A sense of Congress won't end months-long waiting lists for effective 
treatment. A sense of Congress won't get lifesaving overdose reversal 
drugs out to our first responders. If this Congress has any sense, as 
we move into conference committee, we will support this epidemic with 
the robust resources this country deserves for a real and meaningful 
response.
  Mrs. BROOKS of Indiana. Mr. Speaker, I reserve the balance of my 
time.
  Mr. PALLONE. Mr. Speaker, I yield 2 minutes to the gentlewoman from 
California (Ms. Matsui).
  Ms. MATSUI. Mr. Speaker, the opioid and heroin crisis has hit home 
for everyone, impacting our coworkers, our

[[Page H2370]]

neighbors, and our friends in every corner of this country.
  In Sacramento, my district, the deadly consequences of fentanyl are 
devastating our families. The faces behind this tragedy are people like 
28-year-old Jerome Butler, a young father whose life was cut short 
because of a tainted pill.
  The human toll of this crisis demands our leadership. This week, we 
took a step forward by passing a number of bipartisan bills to address 
the opioid epidemic, many of which we worked on in the Energy and 
Commerce Committee.

                              {time}  1100

  But we can and must do more. We need new funding to confront this 
tragedy.
  My Democratic colleagues and I are ready to fund the President's $1.1 
billion request for this crisis. We need a real investment to meet the 
challenges our committees are facing every day.
  As we advance substance abuse legislation and continue our important 
work on comprehensive behavioral health reform, I urge my colleagues to 
focus on solutions that both adequately address the immediate crisis 
and long-term community prevention strategies.
  The families reeling from the tragedies of this epidemic deserve 
nothing less than our swift action and full support.
  Mrs. BROOKS of Indiana. Mr. Speaker, I reserve the balance of my 
time.
  Mr. PALLONE. Mr. Speaker, I yield myself such time as I may consume.
  I rise this morning to speak in favor of the House amendment to S. 
524.
  Over the last 2 days of floor debate, we have heard heartfelt 
speeches from Members of Congress about how the opioid epidemic is 
affecting their constituents and, for some, their own families. We have 
heard from both Democrats and Republicans, Members from urban 
districts, suburban districts, and rural districts, as well as Members 
from every region of the United States.
  What is clear is that no community has been immune to this crisis, 
including communities in my home State of New Jersey. About 256,000 New 
Jersey residents are addicted to heroin and prescription opioids. That 
is nearly the same as the entire population of Newark, the largest city 
in New Jersey.
  This is a serious crisis that demands an urgent response. A 
comprehensive solution to the crisis will require real dollars and must 
take an approach that targets the full spectrum of addiction: 
prevention, crisis response, expanding access to treatment, and 
providing support for lifelong recovery.
  The approach must be guided by science and cannot be deterred because 
of stigma or misperceptions about proven treatment and intervention 
strategies.
  I am pleased to support the package of opioid legislation that we are 
considering today because it takes steps towards that approach.
  This bill incorporates proven public health approaches to fight 
against the heroin and prescription drug abuse crisis. It improves the 
tools available to prescribers to prevent opioid abuse and the 
development of opioid use disorder. It expands access to lifesaving 
naloxone, an opioid overdose-reversal drug, to respond to those in an 
acute opioid crisis. It expands access to evidence-based treatments to 
help individuals with opioid use disorders enter recovery.
  However, Mr. Speaker, I want to make clear we must go further to 
ensure that the scale of our response is proportionate to the burden of 
the crisis. We not only need to support individuals' entry into 
recovery, we need to ensure that we provide access to the support and 
services that lead to lifelong recovery. We must also further expand 
access to bupe, or buprenorphine, an office-based, medication-assisted 
treatment for opioid use disorders.
  Currently, we do not have adequate treatment capacity to respond to 
the unprecedented demand for opioid use disorder treatment. That is why 
we need to expand upon the Opioid Use Disorder Treatment Expansion and 
Modernization Act to significantly increase the number of patients a 
physician can treat with this medication as well as permanently 
allowing nurse practitioners and physician assistants to treat patients 
with this medication.
  In the committee, Democrats voted to raise the cap to 500 patients 
for qualifying physicians with appropriate credentials. Additionally, 
committee Democrats and Republicans voted unanimously to permanently 
allow nurse practitioners and physician assistants to treat patients 
with bupe.
  I am committed to continuing to work with my colleagues as part of 
our conference with the Senate to ensure that we lift the arbitrary and 
harmful physician treatment cap and to ensure that nurse practitioners 
and physician assistants in every community can permanently use their 
skills and experience to serve those in need of opioid use disorder 
treatments in their community.
  Finally, Mr. Speaker, I want to be clear that we should not be under 
the illusion that we can adequately respond to this crisis without 
providing urgently needed resources. Waiting on the appropriation 
process isn't suitable. Our States and communities urgently need money 
now.
  Additionally, we should not be forced to cut other discretionarily 
funded public health programs to provide resources for substance abuse 
programs. The discretionary funding caps have already left many of our 
vital public health programs underfunded.
  Forcing additional cuts to those programs in order to provide funding 
to respond to the opioid epidemic will limit our ability to adequately 
respond to the opioid crisis as well as to meet the remaining public 
health needs of our communities.
  We don't have to guess how it turns out if we fail to provide the 
urgent, robust funding that is desperately needed. Sadly, the evidence 
is already staring us in the face. There will be more lives lost to the 
epidemic and will be thousands more Americans who will continue to be 
left behind to battle without the treatment and recovery support 
services they need.
  We are losing now, we estimate, 78 Americans each day, and we can't 
afford anything less than a comprehensive well-funded Federal response.
  I urge my colleagues to vote ``yes'' to this legislation because I 
believe it takes important steps in turning the tide on this crisis 
that is taking the lives of 78 Americans every day.
  But I also urge my colleagues to support providing the financial 
resources and additional tools necessary to meet the burden of this 
crisis.
  I urge support for this package and once again stress that we are not 
providing enough funding. As much as I believe that this package is 
very important, I certainly would agree with my colleague on the 
Republican side how important it is.
  We are not providing enough resources. I hope that, when we go to 
conference and before this package goes to the President, we can 
provide the additional resources.
  I urge everyone to support the bill.
  I yield back the balance of my time.
  Mrs. BROOKS of Indiana. Mr. Speaker, I yield myself such time as I 
may consume.
  In closing, I would like to emphasize that, as my colleague, the 
ranking member from New Jersey, indicated, we have made real strides 
this week in turning back the epidemic, but we agree it is not enough 
and it is not over. This fight is not going to be over. There is still 
more to be done.
  But I do hope that this week's productivity will lead to more weeks 
where we can continue to engage in a healthy and robust debate about 
the issues that matter. This week has proven we are stronger as a body 
when we focus on the things that unite us and bring us together.
  Sadly, it shouldn't take an epidemic or a national crisis to bring us 
together. This week has taught us that, with enough will and 
dedication, we can get to yes.

  The conference committee, which this bill will initiate, will need 
similar fortitude to swiftly come to a resolution on the differences we 
have with the Senate. That accomplishment is within our grasp.
  We have come too far to turn back now rather than let this issue 
languish. That is why I urge my colleagues to vote in favor of this 
bill, support the motion to go to conference.
  Beyond the 78 Americans who are dying every day, we have 1.9 million 
Americans addicted to or abusing prescription opioid-based painkillers 
across the country. Because of their lives and their families' lives, 
we must pass this bill.

[[Page H2371]]

  I yield back the balance of my time.
  Mr. GOODLATTE. Mr. Speaker, I yield myself such time as I may 
consume.
  It has been quite a week. This week the House has passed 18 bills 
designed to address various facets of America's opioid epidemic. Most 
recently, yesterday, the House passed by an overwhelming 413-5 vote the 
Judiciary Committee's flagship bill.
  H.R. 5046, which was authored by Crime Subcommittee Chairman Jim 
Sensenbrenner, creates a comprehensive Justice Department grant program 
to provide States with the resources needed to fight opioid addiction. 
It authorizes $103 million a year for 5 years for the grant program. It 
allocates precious resources responsibly by leveraging and streamlining 
existing programs and fully offsetting the legislation in compliance 
with the House's CutGo protocol.
  In addition to that bill, the House passed four other Judiciary 
Committee bills this week to address drug abuse and protect American 
people.
  H.R. 5052, the OPEN Act, increases the transparency and 
accountability of the comprehensive opioid abuse grant program in H.R. 
5046 by requiring grantees to report on the use of grant funds and 
requiring a publicly available analysis of whether the grants have 
achieved their intended purposes.
  H.R. 4985, the Kingpin Designation Improvement Act, protects 
classified information from disclosure when a drug kingpin challenges 
his designation as such in a Federal court.
  H.R. 5048, the Good Samaritan Assessment Act, requires the GAO to 
study State and local Good Samaritan laws that protect caregivers, law 
enforcement personnel, and first responders who administer opioid 
overdose reversal drugs or devices from criminal or civil liability as 
well as those who contact emergency service providers in response to an 
overdose.
  Finally, S. 32, the Transnational Drug Trafficking Act, improves law 
enforcement's ability to pursue international drug manufacturers, 
brokers, and distributors in source nations. I am pleased that the 
House took up the Senate version of this bill.
  As a result, that legislation is on its way to the President's desk 
to be signed into law so that Federal prosecutors can begin using that 
tool to pursue foreign drug traffickers.
  Along with the excellent legislation prepared by our sister 
committees, spearheaded by Chairman Upton, Chairman Miller, and 
Chairman Kline, four of the Judiciary Committee bills will be included 
in the House amendment to S. 524, the Senate's Comprehensive Addiction 
and Recovery Act.
  As a package, these bills make substantial policy changes at the 
Federal agencies responsible for fighting addiction. They take real 
steps to address the opioid epidemic and provide real relief to a real 
problem affecting real Americans. Members of this body should be proud 
of these accomplishments.
  In addition to the committee chairmen I mentioned, I also want to 
thank Chairman Harold Rogers, who spoke in support of H.R. 5046 
yesterday and is a strong ally in the fight against elicit opioid 
abuse. I have no doubt that he will make every effort during this 
Congress to provide the critical funding authorized by the bills that 
have passed the House this week.
  Mr. Speaker, I look forward to sending this legislation back to the 
Senate and moving to conference expeditiously. Congressional action to 
combat the opioid epidemic is sorely needed, and there is bipartisan, 
bicameral support for these efforts.
  I thank my colleagues for their support and hard work. I urge 
everyone to support the House amendment to S. 524.
  I thank my colleague, the ranking member of the committee, Mr. 
Conyers, for his hard work on this as well. This truly is a bipartisan 
effort.
  I commend all to support this motion to go to conference.
  I reserve the balance of my time.
  Mr. CONYERS. Mr. Speaker, I yield myself such time as I may consume.
  Members of the House, I rise in support of the House amendment to S. 
524, the Comprehensive Addiction and Recovery Act.
  Before starting out on the merits of the legislation, I want to 
commend the Judiciary Committee chairman, Mr. Goodlatte, for 
shepherding our committee's five bills to House passage.
  I also commend the subcommittee chairman, Mr. Sensenbrenner of 
Wisconsin, for authoring the legislation that is largely responsible 
for bringing us together today.
  I also want to recognize the leadership of the Crime Subcommittee 
ranking member, Sheila Jackson Lee of Texas, who was an original 
cosponsor of the primary Judiciary Committee bill and who has helped us 
find common ground in addressing the issue of drug addiction and 
treatment.
  This week the House considered and passed a wide range of bills aimed 
at combating the devastating impact of drug abuse and addiction that is 
afflicting communities all across our Nation.
  We must take this action because our Nation is in the midst of a 
major public health crisis caused by an epidemic of prescription and 
opioid abuse. It is a crisis that affects Americans of all ages, of all 
races, and of all income levels. It has devastated communities across 
the United States. It affects families, the workplace, and also our 
Nation's economy.

                              {time}  1115

  Drug overdoses are now the leading cause of injury-related deaths in 
our Nation. In my State of Michigan, for example, there were 1,745 drug 
overdose deaths in 2014, and more than half of those overdose deaths 
were attributed to opioids and heroin. In fact, 78 Americans die from 
an opioid overdose every single day. Without question, this is a crisis 
that cries out for immediate relief.
  Fortunately, there may be effective solutions. For example, several 
States have undertaken various innovative measures to better respond to 
the rapid increase of individuals who are addicted to prescription 
opioids and heroin and to prevent individuals from dying as a result of 
drug overdose.
  As I mentioned only yesterday during debate with respect to our 
consideration of H.R. 5046, which has been incorporated into the House 
amendment to S. 524, this measure would fund new, innovative ways to 
address the nationwide epidemic of opioid drug abuse addiction. These 
innovations include, for instance, the Law Enforcement Assisted 
Diversion approach, which has been utilized with great success in two 
cities of which I know--in Seattle and in Santa Fe. Programs such as 
this diversion approach underscore the fact that we cannot arrest our 
way out of opioid abuse addiction. Treating addicts as criminals only 
makes matters worse for them and also for the rest of us.
  The diversion approach, which reduces, by the way, recidivism by 60 
percent, is just one example of innovation at the State and local 
levels that we must encourage through increased funding assistance, and 
it is more evidence that treatment alternatives to incarceration work.
  The funding authorized under this measure would establish a 
competitive grant program to provide funds to State and local 
governments to continue and improve their efforts to protect Americans 
from the dangers of opioid abuse and heroin use; and it will help 
ensure that addicts have access to the services that are provided.
  These funds would support such initiatives as providing treatment 
alternatives to incarceration; fostering better collaboration between 
State criminal justice agencies and state substance abuse systems; 
providing first responders with the ability to purchase naloxone and to 
receive training on how to administer this lifesaving drug; 
establishing medication-assisted treatment programs by criminal justice 
agencies; in addition, investigating more of the illegal distribution 
methods of opioids; creating Prescription Drug Monitoring Programs; 
addressing juvenile opioid abuse, which is, unfortunately, increasing; 
and establishing comprehensive opioid abuse response programs.
  The House amendment to S. 524 also includes a number of important 
provisions that have been added pursuant to a series of amendments that 
were passed by the House only yesterday.
  In sum, these additional provisions expand the range of allowed 
purpose areas under the new program to more fully address the range of 
problems and

[[Page H2372]]

solutions that are presented by opioid abuse. Whether we provide 
separate, new grant programs for each of these approaches or whether we 
consolidate them into one grant program, it is critical that we change 
our ways of addressing addiction. The scourge of drug abuse and its 
overwhelming impact on our communities requires us to address this 
problem not only immediately, but effectively.
  I thank all of the committees and individuals who have participated 
in this effort. Accordingly, I support House amendment S. 524.
  I reserve the balance of my time.
  Mr. GOODLATTE. Mr. Speaker, I do not have any speakers remaining, and 
I am prepared to close.
  I reserve the balance of my time.
  Mr. CONYERS. Mr. Speaker, I yield myself such time as I may consume.
  I support the House amendment to S. 524 because it will help address 
our Nation's crisis of opioid abuse and heroin use. My support for this 
legislation is based, in part, on the fact that it includes H.R. 5046, 
which is legislation that I have worked on with my colleagues on both 
sides of the aisle, that would provide critical grants to States and 
local governments, intended to prevent and treat opioid abuse 
addiction. Most importantly, I support this legislation because it 
would help save lives.
  The House amendment to S. 524 provides a comprehensive approach to 
the opioid substance abuse public health emergency that is currently 
ravaging our Nation. Accordingly, I urge my colleagues to support this 
measure.
  Mr. Speaker, I yield the balance of my time to the gentlewoman from 
Texas (Ms. Jackson Lee).
  Ms. JACKSON LEE. Let me thank Mr. Goodlatte, Mr. Conyers, the 
Judiciary Committee, and Mr. Sensenbrenner, who mentioned yesterday 
that he had been working on this for 2 years. We have joined him as the 
original cosponsors in supporting this on the Subcommittee on Crime, 
Terrorism, Homeland Security, and Investigations, of which I am the 
ranking member, along with Mr. Sensenbrenner, and this is a moment that 
all of us are appreciative of.
  Mr. Speaker, as I thought about this week, during which we are 
honoring police and we are also acknowledging those who have fallen in 
the line of duty, this bill, the Comprehensive Addiction and Recovery 
Act, becomes even more important. This week, the House adopted a number 
of bills that, together, are intended to provide a response to the 
opioid crisis that is commensurate with the scope of the problem.
  Yesterday the House passed, by an overwhelming vote, the primary 
contribution of the Judiciary Committee's to this effort, H.R. 5046, 
the Comprehensive Opioid Reduction Act. I am an original cosponsor of 
that bill, and I was a cosponsor of the predecessor bill, both of which 
were introduced by my colleague, Jim Sensenbrenner, the chairman of the 
subcommittee.
  I commend him for the years of work and persistence on this issue. I 
also commend Chairman Goodlatte and Ranking Member Conyers for their 
leadership, for it would not have been shepherded through the committee 
if we had not all worked together to find common ground on this very 
important issue.
  That has been the trend of the Judiciary Committee's as we work on 
criminal justice reform, which includes sentencing reduction and prison 
reform--provocative, innovative bills that are going to change the 
lives of many of those who are incarcerated for many, many years. We 
are going to turn mass incarceration upside down and on its ears and 
cause it to be extinct. This new approach to opioids is part of that.
  This bill has no mandatory minimums. As we take the steps today which 
will allow us to engage in discussions with the Senate so that we may 
soon send a bill to the President for his signature, I am pleased of 
the progress that has been made. I can only hope that our work on 
sentencing reduction, prison reform, and juvenile justice will have the 
same kind of impetus and will wind up on the President's desk. That is 
the vision, I believe, of many Republicans and Democrats in and out of 
this House. As well, it is the vision of the President's; but, more 
importantly, it is the vision of suffering families' who do not have 
their loved ones with them.
  The reason we must work together is that the leading killer of 
Americans today, which is drug overdose, started first by prescription 
use in many instances. Between 2000 and 2014, almost half a million 
people died from drug overdoses. That is a startling number. In 2014 
alone, more than 47,000 people died of drug overdoses. The largest 
percentage of overdose deaths in 2014 was attributed to opioids, like 
prescription painkillers, methadone, morphine, and heroin. 
Specifically, 28,647 people overdosed and died because of an opioid in 
2014.
  This is an emergency, and it is a combination of prescription 
painkillers and heroin. Prescription painkillers abuse is the strongest 
risk for the future use of heroin. That is our athletes or those who 
have had surgery--just everyday Americans who find themselves caught in 
the trap of addiction. Approximately three out of four new heroin users 
report that their use began with the abuse of prescription drugs. 
Heroin use becomes appealing to those who are addicted to prescription 
drugs because it is cheaper and easier to obtain, and due to its 
potency, heroin use tends to lead to addiction. We know that from the 
1980s and 1990s with crack cocaine in that crack was a more potent 
extraction of cocaine, and we saw many of those individuals not get 
treatment. They actually only got incarceration. Heroin addiction is 
often deadly just as crack cocaine was in leading to overdose or to 
other chronic diseases.
  The rate at which the occurrence of heroin overdose deaths has 
increased is cause for alarm. In the 4 years between 2010 and 2014, 
heroin overdoses more than tripled. In 2013, 11 million people admitted 
to the improper use of prescription painkillers and, therefore, were at 
a heightened risk of becoming addicted.
  That is why we have worked together this week on legislation to put 
together something like an omnibus in order to reduce the risks of 
addiction and to fund appropriate treatment responses for those who 
abuse these drugs. The bill that was passed yesterday reflects the 
strategy by proposing to establish a grant program to be administered 
by the Department of Justice to assist States and local governments.
  It is important to note these statistics: the rate of deaths from 
heroin overdoses that account from the White population saw a 267 
percent increase between 2010 and 2014; in African Americans, there was 
an increase of 213 percent in 2010 to 2014; in Hispanics, there was a 
137 percent increase from 2010 to 2014; and in Native Americans, there 
was a 236 percent increase.
  No aspect of American life has been uninfluenced by the devastation 
of heroin overdoses and deaths--many of it impacting families whose 
young, bright, talented, athletic, and, otherwise, young people have 
fallen victim to this. This grant program is extremely helpful, for 
which I am very pleased, because it deals with monitoring the 
prescription drugs, and it deals with matching those who are committed 
to working with police officers. It is truly an important bill.
  Let me close by saying that we must have money to support all of 
this, and I am hoping that this will not be the last stop we will make.
  Mr. Speaker, I rise in support of this amendment to S. 524, the 
Comprehensive Addiction and Recovery Act.
  This week, the House adopted a number of bills that--together--are 
intended to provide a response to the opioid crisis that is 
commensurate with the scope of the problem.
  Yesterday, the House passed--by an overwhelming vote--the primary 
contribution of the Judiciary Committee to this effort, H.R. 5046, the 
Comprehensive Opioid Abuse Reduction Act.
  I am an original cosponsor of that bill, and I was a cosponsor of the 
predecessor bill, both of which were introduced by my colleague, Jim 
Sensenbrenner, the Chairman of the Subcommittee on Crime.
  I commend him for his years of work and persistence on this issue, 
and I also commend Chairman Goodlatte and Ranking Member Conyers for 
their leadership and work to find common ground on this very important 
issue.
  As we take the steps today which will allow us to engage in 
discussions with the Senate so that we may soon send a bill to the 
President for signature, I am pleased at the progress we have made.

[[Page H2373]]

  The reason we must work together is that a leading killer of 
Americans today is drug overdose.
  Between 2000 and 2014, almost half a million people died from drug 
overdoses.
  In 2014 alone, more than 47,000 people died of drug overdoses.
  The largest percentage of overdose deaths in 2014 was attributed to 
opioids--like prescription painkillers, methadone, morphine, and 
heroin.
  Specifically, 28,647 people overdosed and died because of an opioid 
in 2014.
  This emergency is compounded due to the perilous connection between 
prescription painkillers and heroin.
  Prescription painkiller abuse is the strongest risk factor for future 
heroin use.
  Approximately three out of four new heroin users report that their 
use began with their abuse of prescription painkillers.
  Heroin use becomes appealing to those addicted to prescription 
painkillers because it is cheaper and easier to obtain.
  Due to its potency, heroin use tends to lead to addiction.
  Heroin addiction is often deadly, leading to overdose or other 
chronic diseases.
  The rate at which the occurrence of heroin overdose deaths increased 
is cause for alarm.
  In the four years between 2010 and 2014, heroin overdoses more than 
tripled.
  In 2013, 11 million people admitted to improper use of prescription 
painkillers and therefore were at a heightened risk of becoming 
addicted to heroin--with its attendant risks and dangers.
  That is why we have worked together this week on legislation to 
reduce the risks of addiction and to fund appropriate treatment 
responses to those who abuse these drugs.
  The bill we passed yesterday, H.R. 5046, reflects this strategy by 
proposing to establish a grant program, to be administered by the 
Department of Justice, to assist states and local governments, 
particularly by helping criminal justice agencies to tackle the opioid 
problem from a variety of angles.
  This bill, included in this amendment, encourages the development of 
alternatives to incarceration that provide treatment as a solution to 
the underlying motivation for criminal behavior or conduct associated 
with mental disorders.
  We must make our best efforts to prevent individuals from moving from 
painkillers to heroin by making treatment for addicts more accessible 
by encouraging the use of evidence-based programs, such as medication-
assisted treatment.
  Life-saving overdose reversal drugs, like naloxone, are most valuable 
in the hands of trained individuals who regularly come in contact with 
individuals who are prone to drug overdoses.
  This legislation will increase the use and availability of naloxone 
and other overdose reversal drugs to first responders.
  Addiction is a disease that affects the brain and eventually changes 
the behavior of addicts, causing them to experience mental health 
issues and encounter legal problems.
  Treatment is the most reasonable and effective approach to diverting 
these individuals away from homelessness and prison.
  There are also specific provisions we have proposed that allow for a 
wide range of services to be offered to our veterans who tend to suffer 
from mental health issues and addiction.
  I support this legislation because I believe that it will help save 
lives and prevent and treat opioid addiction.
  The approach Congress is taking with the crisis of heroin and other 
opioids is thoughtful and comprehensive.
  I hope it signals a departure from some of the failed approaches 
concerning other drug crises in the past.
  For instance, our response to the surge in crack cocaine in the 1980s 
was to enact draconian mandatory minimum penalties with vastly 
disparate treatment for crack and powder cocaine.
  At that time, we in Congress took action that we are still trying to 
rectify.
  At one point, more than 80% of the defendants sentenced for crack 
offenses were African American, despite the fact that more than 66% of 
crack users are white or Hispanic.
  As we work on other legislation to address the enforcement and 
sentencing disparities related to the crack issue, we must re-examine 
our approach to that and other drug issues.
  While law enforcement has an appropriate role and the bills recognize 
that, the bills we adopted this week and that we put forth as an 
amendment to the Senate bill today reflect a broader strategy that 
reflects the fact that this is an addiction issue.
  Accordingly, we are not raising sentences or impacting mandatory 
minimums but we are funding anti-addiction mechanisms such as treatment 
alternatives to incarceration.
  We are not adding to mass incarceration--with all of the related and 
devastating collateral consequences--but instead we are incentivizing 
state and local governments to prevent, treat, and heal.
  That is what we should be doing, and that is what we should have done 
for crack and cocaine addicts.
  With that history in mind and with the chance to take smarter and 
more effective steps now, I look forward to continuing to work with my 
colleagues in the House--and in the Senate--to apply this more 
comprehensive approach, including treatment alternatives, to those 
suffering from crack and cocaine addiction.
  Yesterday, in my closing remarks on H.R. 5046, I stated my intention 
to ensure that we make progress on addiction not only involving opioids 
but drugs like crack and powder cocaine as well.
  As I express my support for this legislation, I urge my colleagues to 
work with me in this broader initiative as well as join me in voting 
for this amendment to the Senate bill today.
  Mr. CONYERS. Mr. Speaker, I yield back the balance of my time.
  Mr. GOODLATTE. Mr. Speaker, I yield back the balance of my time.
  The SPEAKER pro tempore. All time for debate has expired.
  Pursuant to House Resolution 725, the previous question is ordered on 
the bill, as amended.
  The question is on the third reading of the bill.
  The bill was ordered to be read a third time, and was read the third 
time.
  The SPEAKER pro tempore. The question is on the passage of the bill.
  The question was taken; and the Speaker pro tempore announced that 
the ayes appeared to have it.
  Mr. GOODLATTE. Mr. Speaker, on that I demand the yeas and nays.
  The yeas and nays were ordered.
  The vote was taken by electronic device, and there were--yeas 400, 
nays 5, not voting 28, as follows:

                             [Roll No. 193]

                               YEAS--400

     Abraham
     Aderholt
     Aguilar
     Allen
     Amodei
     Ashford
     Babin
     Barletta
     Barr
     Barton
     Beatty
     Becerra
     Benishek
     Bera
     Beyer
     Bilirakis
     Bishop (GA)
     Bishop (MI)
     Bishop (UT)
     Black
     Blackburn
     Blum
     Blumenauer
     Bonamici
     Bost
     Boustany
     Boyle, Brendan F.
     Brady (PA)
     Brady (TX)
     Brat
     Brooks (IN)
     Brown (FL)
     Brownley (CA)
     Buchanan
     Buck
     Bucshon
     Bustos
     Butterfield
     Byrne
     Calvert
     Capps
     Capuano
     Carney
     Carson (IN)
     Carter (GA)
     Carter (TX)
     Cartwright
     Castor (FL)
     Castro (TX)
     Chabot
     Chaffetz
     Chu, Judy
     Cicilline
     Clark (MA)
     Clarke (NY)
     Clawson (FL)
     Clay
     Cleaver
     Clyburn
     Coffman
     Cohen
     Cole
     Collins (GA)
     Collins (NY)
     Comstock
     Conaway
     Connolly
     Conyers
     Cook
     Cooper
     Costa
     Costello (PA)
     Courtney
     Cramer
     Crawford
     Crenshaw
     Crowley
     Cuellar
     Culberson
     Cummings
     Curbelo (FL)
     Davis (CA)
     Davis, Danny
     Davis, Rodney
     DeFazio
     DeGette
     Delaney
     DeLauro
     DelBene
     Denham
     Dent
     DeSantis
     DeSaulnier
     DesJarlais
     Deutch
     Diaz-Balart
     Dingell
     Doggett
     Dold
     Donovan
     Doyle, Michael F.
     Duckworth
     Duffy
     Duncan (SC)
     Duncan (TN)
     Edwards
     Ellison
     Ellmers (NC)
     Emmer (MN)
     Engel
     Eshoo
     Esty
     Farenthold
     Farr
     Fitzpatrick
     Fleischmann
     Fleming
     Flores
     Fortenberry
     Foster
     Foxx
     Frankel (FL)
     Franks (AZ)
     Frelinghuysen
     Fudge
     Gabbard
     Gallego
     Garrett
     Gibbs
     Gibson
     Goodlatte
     Gosar
     Gowdy
     Graham
     Granger
     Graves (GA)
     Graves (LA)
     Graves (MO)
     Grayson
     Green, Al
     Green, Gene
     Griffith
     Grijalva
     Grothman
     Guinta
     Guthrie
     Gutierrez
     Hahn
     Hanna
     Hardy
     Harper
     Harris
     Hartzler
     Heck (NV)
     Heck (WA)
     Hensarling
     Hice, Jody B.
     Higgins
     Hill
     Himes
     Hinojosa
     Holding
     Honda
     Hoyer
     Hudson
     Huelskamp
     Huffman
     Huizenga (MI)
     Hultgren
     Hunter
     Hurd (TX)
     Hurt (VA)
     Issa
     Jackson Lee
     Jeffries
     Jenkins (KS)
     Jenkins (WV)
     Johnson (GA)
     Johnson (OH)
     Johnson, E. B.
     Johnson, Sam
     Jolly
     Jones
     Jordan
     Joyce
     Kaptur
     Katko
     Keating
     Kelly (IL)
     Kelly (MS)
     Kelly (PA)
     Kildee
     Kilmer
     Kind
     King (IA)
     King (NY)
     Kinzinger (IL)
     Kline
     Kuster
     Labrador
     LaHood
     LaMalfa
     Lamborn
     Lance
     Langevin
     Larsen (WA)
     Larson (CT)
     Lawrence
     Lee
     Levin
     Lewis
     Lieu, Ted
     Lipinski
     LoBiondo
     Loebsack
     Lofgren
     Long
     Loudermilk
     Love
     Lowenthal
     Lowey
     Lucas
     Luetkemeyer
     Lujan Grisham (NM)
     Lujan, Ben Ray (NM)
     Lummis
     Lynch
     MacArthur
     Maloney, Carolyn
     Maloney, Sean
     Marchant
     Marino
     Matsui
     McCarthy
     McCaul
     McClintock
     McCollum
     McDermott
     McGovern
     McHenry
     McKinley
     McMorris Rodgers
     McNerney
     McSally
     Meadows
     Meehan
     Meeks
     Meng
     Messer
     Mica
     Miller (FL)
     Miller (MI)
     Moolenaar
     Mooney (WV)
     Moore
     Moulton
     Mullin
     Mulvaney

[[Page H2374]]


     Murphy (FL)
     Murphy (PA)
     Nadler
     Napolitano
     Neal
     Neugebauer
     Newhouse
     Noem
     Nolan
     Norcross
     Nugent
     Nunes
     O'Rourke
     Olson
     Palazzo
     Pallone
     Palmer
     Paulsen
     Pearce
     Pelosi
     Perlmutter
     Perry
     Peters
     Peterson
     Pingree
     Pittenger
     Pocan
     Poe (TX)
     Poliquin
     Polis
     Pompeo
     Posey
     Price (NC)
     Price, Tom
     Quigley
     Rangel
     Ratcliffe
     Reed
     Reichert
     Renacci
     Ribble
     Rice (NY)
     Rice (SC)
     Rigell
     Roby
     Roe (TN)
     Rogers (AL)
     Rogers (KY)
     Rohrabacher
     Rokita
     Rooney (FL)
     Ros-Lehtinen
     Roskam
     Ross
     Rothfus
     Rouzer
     Roybal-Allard
     Royce
     Ruiz
     Ruppersberger
     Ryan (OH)
     Sanchez, Linda T.
     Sanchez, Loretta
     Sarbanes
     Scalise
     Schakowsky
     Schiff
     Schrader
     Schweikert
     Scott, Austin
     Scott, David
     Sensenbrenner
     Serrano
     Sessions
     Sewell (AL)
     Sherman
     Shimkus
     Shuster
     Simpson
     Sinema
     Sires
     Slaughter
     Smith (MO)
     Smith (NE)
     Smith (NJ)
     Smith (TX)
     Smith (WA)
     Stefanik
     Stewart
     Stivers
     Swalwell (CA)
     Takai
     Takano
     Thompson (CA)
     Thompson (MS)
     Thompson (PA)
     Thornberry
     Tiberi
     Tipton
     Tonko
     Torres
     Trott
     Tsongas
     Turner
     Upton
     Valadao
     Van Hollen
     Vargas
     Veasey
     Vela
     Velazquez
     Visclosky
     Wagner
     Walberg
     Walden
     Walker
     Walorski
     Walters, Mimi
     Walz
     Wasserman Schultz
     Waters, Maxine
     Watson Coleman
     Weber (TX)
     Webster (FL)
     Welch
     Wenstrup
     Westerman
     Westmoreland
     Williams
     Wilson (FL)
     Wilson (SC)
     Wittman
     Womack
     Woodall
     Yarmuth
     Yoder
     Yoho
     Young (AK)
     Young (IA)
     Young (IN)
     Zeldin
     Zinke

                                NAYS--5

     Amash
     Brooks (AL)
     Gohmert
     Massie
     Scott (VA)

                             NOT VOTING--28

     Adams
     Bass
     Bridenstine
     Burgess
     Cardenas
     Fattah
     Fincher
     Forbes
     Garamendi
     Hastings
     Herrera Beutler
     Israel
     Kennedy
     Kirkpatrick
     Knight
     Latta
     Pascrell
     Payne
     Pitts
     Richmond
     Rush
     Russell
     Salmon
     Sanford
     Speier
     Stutzman
     Titus
     Whitfield

                              {time}  1151

  Mr. SCOTT of Virginia changed his vote from ``yea'' to ``nay.''
  So the bill was passed.
  The result of the vote was announced as above recorded.
  Pursuant to section 3 of House Resolution 725, the title of the bill 
was amended so as to read: ``An Act to authorize the Attorney General 
and Secretary of Health and Human Services to award grants to address 
the national epidemics of prescription opioid abuse and heroin use, and 
to provide for the establishment of an inter-agency task force to 
review, modify, and update best practices for pain management and 
prescribing pain medication, and for other purposes.''.
  A motion to reconsider was laid on the table.
  Stated for:
  Mr. SCOTT of Virginia. Mr. Speaker, I inadvertently voted NAY on 
passage of S. 524, as amended by the House. I strongly support S. 524, 
as amended by the House.


                          Personal Explanation

  Mr. SANFORD. Mr. Speaker, because I was in Nashville, Tennessee 
attending my son Landon's graduation from Vanderbilt University today, 
I was not present to vote. Had I been present, I would have voted 
``yea'' on rollcall 190, ``aye'' on rollcall 191, ``yea'' on rollcall 
192, and ``nay'' on rollcall 193.


                          Personal Explanation

  Mr. KNIGHT. Mr. Speaker, on Friday, May 13th, I was absent due to 
obligations in the district. Had I been present for the day's vote 
series, I would have voted ``yea'' on rollcall No. 190, on ordering the 
previous question; ``yea'' on rollcall No. 191, on the rule providing 
for the consideration of S. 524; ``nay'' on rollcall No. 192, on 
approval of the journal; and ``yea'' on rollcall No. 193, on passage of 
S. 524 or the Comprehensive Addiction and Recovery Act of 2016, as 
modified by the House amendment.

                          ____________________